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Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder 
characterised by abdominal pain and abnormal bowel function. The diagnosis of IBS is 
based on symptom description as no organic, biochemical or structural abnormalities are 
present. In epidemiologic studies, the prevalence of IBS ranges between 3 and 25%, 
usually with an over-representation of the female gender. The wide variation in prevalence 
estimates is partly due to various IBS definitions and diagnostic criteria. The most 
frequently used symptom based criteria include Manning, Rome I, and Rome II criteria. 
Manning criteria generally give a higher prevalence estimate than Rome II criteria.  
IBS is associated with a high rate of psychological and somatic comorbid conditions, 
such as depression, anxiety, dyspepsia, headache, lower back pain, and fibromyalgia. 
Moreover, IBS is associated with a high rate of health care consumption for both GI and 
non-GI reasons. IBS sufferers miss work for illness almost three times as often as controls. 
Therefore, IBS incurs significant direct and indirect health care costs for society.  
The aim of this study was to assess the prevalence of IBS among subjects of working 
age according to various diagnostic criteria. In addition, we studied the rates of somatic 
and psychiatric comorbidity and health care consumption for GI and non-GI reasons, as 
well as predictors of health care seeking. Finally, we evaluated the societal costs of IBS.  
 
Methods: The study was a two-phase postal survey. In phase I, a questionnaire covering 
GI symptoms according to Manning 2 (at least two of the six Manning symptoms), 
Manning 3 (at least three Manning symptoms), Rome I, and Rome II criteria, was mailed 
to 5 000 randomly selected non-institutionalised Finnish residents aged 18 to 64. The 
questionnaire also included a Finnish modification of the Beck Depression Inventory 
Short Form (BDI-SF) and items covering the severity of GI symptoms, rates of headaches, 
back pain, and dyspeptic symptoms. In addition, health care consumption for GI and non-
GI reasons and work absenteeism for GI reasons was inquired. In phase II, a questionnaire 
covering rates of GI health care visits in primary and secondary care, use of GI 
medication, and the duration of GI symptoms, was sent to subjects fulfilling IBS criteria 
according to Manning 2 or Rome II criteria in the phase I questionnaire. 
 
Results: The response rate was 73% and 86% for questionnaires I and II. After adjusting 
for age and gender, the prevalence of IBS was 15.9% (95% CI 14.7-17.1%), 9.6% (95% 
CI 8.6-10.6%), 5.6% (95% CI 4.8-6.4%), and 5.1% (95% CI 4.4-5.8%) according to 
Manning 2, Manning 3, Rome I, and Rome II criteria. Of those meeting Rome II criteria, 
97% also met Manning 2 criteria.  
The prevalence of depressive symptoms in the general population was 16.7% (95% CI 
15.4-17.9%). Of subjects with depressive symptoms, 11.6% met Rome II IBS criteria 
compared to 3.7% of those with no depressiveness (p < 0.0001). In addition, subjects with 
depressive symptoms reported more physician visits and sick leave days for GI symptoms 
than those without.  
Presence of dyspeptic symptoms, lactose intolerance, headache, back pain, depressive 






criterion than by controls not meeting the criterion. In addition, presence of asthma or an 
allergic condition was more common among those fulfilling Manning 2, Manning 3, or 
Rome II criteria than among controls. Presence of severe or very severe abdominal pain 
and disturbance of daily activities by abdominal pain were more often reported by subjects 
meeting either of the Rome criteria than those meeting either of the Manning criteria.  
During the previous year, a larger share of subjects meeting any IBS criteria had made 
GI and non-GI physician visits than controls. In addition, subjects fulfilling either of the 
Rome criteria more often reported GI physician visits than those fulfilling either of the 
Manning criteria. Intensity of GI symptoms and presence of dyspeptic symptoms were the 
strongest predictors of GI consultations, but also headaches, insomnia, and presence of a 
chronic illness were independent predictors. For non-GI visits, presence of chronic illness, 
back pain, and depressive symptoms were the strongest predictors. In addition, presence of 
dyspeptic symptoms and a history of abdominal pain in childhood also predicted non-GI 
visits.  
Annual GI related individual costs were higher in the Rome II group (497€, 95% CI 
382-621€) than in the Manning 2 group (295€, 95% CI 246-347€). The nationwide annual 
GI related expenses were higher by Manning 2 criteria than Rome II criteria (154M€, 95% 
CI 128-181M€ vs. 82M€, 95% CI 63-103M€). Direct expenses of GI symptoms and 
non-GI physician visits ranged between 98M€ for Rome II and 230M€ for Manning 
criteria. 
 
Conclusions: The prevalence of IBS shows substantial variation depending on the criteria 
applied. Rome II criteria are more restrictive than Manning 2 criteria, and they identify an 
IBS population with more severe GI symptoms, more frequent health care use, and higher 
individual health care costs. In the general population, subjects with IBS demonstrate high 
rates of psychiatric and somatic comorbidity regardless of health care seeking status. 
Perceived symptom severity rather than psychiatric comorbidity predicts health care 
seeking for GI symptoms. Depressive symptoms are prevalent in the general population 
and they are associated with an elevated rate of GI symptoms, physician visits, and work 
absenteeism for GI symptoms. 
IBS imposes a significant impact on national health care expenditures. The direct GI 
and non-GI costs of IBS are equivalent to up to 5% of outpatient health care and medicine 
costs in Finland. A more integral approach to IBS by physicians, accounting also for 
comorbid conditions, may produce a more favourable course in IBS patients and reduce 










Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal (GI) disorder 
characterised by abdominal pain or discomfort and altered bowel habits. The aetiology of 
IBS is multifactorial with altered visceral sensitivity, altered gastrointestinal motility, and 
psychosocial factors influencing symptom generation.  
The prevalence of IBS varies worldwide, affecting 3 to 25% of the population. Up to 
90% of subjects with IBS demonstrate comorbid somatic or psychiatric symptoms. They 
make more health care visits than the control population without IBS. Work absenteeism 
due to IBS symptoms is as frequent as that of common cold. Direct and indirect costs of 
IBS incur considerable societal economic burden.  
The definition and diagnostic criteria of IBS has changed over time. In 1978 Manning 
et al. presented the first symptom based criteria for IBS, widely applied later in 
epidemiological research. In 1989, the Rome criteria were introduced and later modified 
as Rome I, Rome II, and Rome III criteria.  
The wide variation in the prevalence of IBS may reflect true differences between 
various populations and countries. Differences in IBS definitions and study 
methodologies, however, hamper reliable comparison between previous studies.  
The main aim of this thesis was to assess the prevalence of IBS according to varying 
diagnostic criteria in a randomly selected population sample and to compare 
sociodemographic, symptom characteristics, and health care use between subjects meeting 
varying IBS criteria and a control population. The thesis also aimed to compare rates of 
comorbid psychiatric and somatic conditions between those meeting IBS criteria and a 
control population, and evaluate their influence on the use of health care facilities among 







2. REVIEW OF THE LITERATURE 
Definition, natural history, and prognosis of irritable bowel 
syndrome (IBS)  
In medical literature, a description of IBS-type symptoms can be found as early as 1820
1
. 
The symptoms included “occasional pain in the intestines and derangement of their 
powers of digestion, with flatulence, and a sense of suffocation”. Since that, these 









, and “irritable colon syndrome”
6
.  
Nowadays, IBS is defined as “a functional bowel disorder in which abdominal pain or 
discomfort is associated with defecation or a change in bowel habit, and with features of 
disordered defecation”
7
.  The term “functional” refers to absence of any organic disease, 
or structural or biochemical abnormality causing the symptoms. Abdominal pain or 
discomfort relieved by defecation indicates a possible colonic source, and appearance of 
pain associated with a change in bowel habits is indicative of a change in intestinal transit 
time, which may be a result of a change in intestinal motor or secretory function
8
.   
Symptoms of IBS follow a chronic relapsing course.  After one to ten years of 
follow-up, 50 to 70% of subjects still fulfil IBS criteria
9-11
. The mean duration of GI 
symptoms among current IBS sufferers ranges between 5 and 13 years. A long history of 
GI symptoms and ongoing life stress are predictors of persisting symptoms
8
.  
IBS is a benign disorder with no reported increased mortality in itself
12
. IBS is, 
however, associated with an increased level of abdominal surgery
13,14
, which may, 
together with unnecessary medical procedures, produce a source of elevated mortality rate 
not detected in studies so far
15
. Despite a benign nature, IBS reduces the quality of life 





The pathogenesis of IBS is not fully understood. Abnormal motor function, visceral 
hypersensitivity, abnormal central nervous processing of visceral stimuli, gastrointestinal 
infections, subtle inflammation, psychosocial factors, abnormal gas handling, alterations 




The enteric nervous system (ENS) is a neural network coating the GI tract. Together 
with the sympathetic and parasympathetic system it forms the autonomic nervous system. 
The ENS integrates the contraction of smooth muscles, intestinal transport of water and 
electrolytes, intestinal secretion, and intramural blood flow. It contains sensory and motor 
neurons, interneurons and several neurotransmitters, such as serotonin 
(5-hydroxytryptamine; 5-HT), acetylcholine, opioids, noradrenaline, somatostatin, 
14
cholecystokinin, substance P, and vasoactive intestinal polypeptide. It functions semi-
autonomously, receiving input from the motor outflow of the sympathetic and 
parasympathetic systems and sending sensory information to the central nervous system 
(CNS)18,19. According to a biopsychological conceptualisation, the brain-gut interaction 
between psychosocial and physiological factors influence GI symptom generation and 























Figure 1. IBS conceptual model. IBS, irritable bowel syndrome; CNS, central nervous system; 
ENS, enteric nervous system.  
Proximal colonic transit is accelerated in IBS with diarrhoea (IBS-D)21. In idiopathic 
constipation, both slowing of the whole colon and left colon transit is reported22. Also, 
altered small bowel transit with a correlation of GI symptoms23 and abnormal response to 
stimuli, such as food and fatty acids, have been described24.    
IBS patients have a lower visceral pain threshold for both mechanical distension25-27
and electrical stimuli28,29 than controls, suggesting that primary afferent neurones (PAN) 
of the enteric nervous system are hypersensitive to non-noxius stimuli30. Some studies 
indicate that they also have cutaneous hyperalgesia28,31,32.  
Functional magnetic resonance imaging (fMRI) and proton emission tomography 
(PET) studies show aberrant brain activation during noxius rectal distention and in the 
anticipation of rectal pain among IBS patients33-35, suggestive of abnormal central 
processing of the visceral stimuli. In an experimental fMRI study, amitriptyline reduced 






cognitive therapy reduced limbic activity, GI symptoms, and anxiety
37
, suggesting that 
cortical processing influences IBS symptoms. In addition, rectal stimulation at distension 
pressures below conscious perception show abnormal CNS activation in IBS patients, 




Depression, anxiety, psychological distress, and stressful life events are more common 
among subjects with unexplained medical symptoms and increased use of healthcare 
services
39
. Regardless of healthcare seeking status, an association between IBS and 
psychiatric distress has been established
40-42
. In addition, over-representation of physical 
or sexual abuse has been reported in IBS patients
43-45
. Psychiatric disorders, especially 
anxiety, may precede the occurrence of GI symptoms and thus have a pathogenetic role in 
the development of IBS, with a link to affective sprectrum disorders
46,47
. 
Infectious gastroenteritis precedes the onset of IBS in 6 to 17% of IBS patients
48
. The 
relative risk of developing IBS after infection increases 10 to 12 times compared to 
uninfected controls
49,50
. An increased number of mucosal lymphocytes, EC cells, higher 
levels of proinflammatory cytokines, and increased gut permeability are associated with 
post infective IBS
51-54
. In addition, regardless of a history of gastroenteritis, neuronal 
degeneration in the jejunal myenteric plexus has been detected
55
, as well as activation of 
the mucosal immune system, especially in IBS-D
56,57
. Inflammatory changes in IBS and 
functional dyspepsia have even been reported in duodenal mucosa
58
. A recent study found 
elevated levels, similar to those in active ulcerative colitis, of faecal human β-defensin-2 
in IBS-D and mixed IBS (IBS-M) patients compared to healthy controls, supporting an 
activation of the mucosal innate defence system
59
. IBS patients also have an increased 
frequency of activated T and B cells in their blood, consistent with a low grade 
inflammation
60,61
. One study reported a correlation between the severity of abdominal pain 
and activated mast cells in close proximity to mucosal nerve endings, suggestive of a 
peripheral mechanism of pain
62
. Moreover, IBS-D patients have displayed enhanced 
proinflammatory cytokine release associated with GI symptoms and anxiety
63
.  
Abdominal bloating, reported by up to 96% of IBS patients, is often the most 
bothersome symptom
64
. IBS patients have shown impaired gas transit, without signs of 
excess intra-abdominal gas
8
. Bloating alone is associated with visceral hypersensitivity, 
while patients with bloating and an increase in girth have normal sensory thresholds 
suggesting different pathogenetic mechanisms of the symptoms
65
. Bloating alone is 
reported more in IBS-D, while bloating with an increment in abdominal girth in IBS with 
constipation (IBS-C)
8
.   
Microbial genome analysis has revealed differences in the intestinal microbiota 
between IBS patients and healthy controls as well as between IBS subgroups, suggesting 
that intestinal bacteria also play a role in IBS development
30,66
.   
Genetic factors may influence development of IBS. Subjects who have a family 
member with GI symptoms are at a more than twofold risk of IBS-type symptoms, but 
having a spouse with these symptoms does not increase the risk
67
. Genetics appear to have 
a role in functional bowel disorders, since a concordance of 33% between monozygotic 
twins and 13% between dizygotic twins has been reported, referring to a 57% share for 








study concluded that social learning has an equal, or greater, influence than genetics on 
IBS development
69
. A genetic component has also been reported for extra-intestinal 
symptoms associated with IBS
70
. In addition, genetic polymorphism of serotonin 




Diagnostic tests are performed to rule out organic diseases that may produce similar 
symptoms to IBS. Negative exclusion diagnosis by means of endoscopic, radiographic, 
and laboratory investigations is, however, costly and inconvenient for the patient.  In order 
to turn IBS diagnosis into a positive symptom based diagnosis, Manning et al. introduced 
the first symptom-based diagnostic criteria for IBS  in 1978 (Table 1). The more of the six 
symptoms present, the more accurately patients with IBS were discriminated from those 
with organic disease. Three of the six symptoms were pain related. In their study, 31 of the 
32 outpatients with IBS had abdominal pain, but no information of the duration or 
frequency was given
73
. Two of the six symptoms were present in 94% of patients with IBS 
and 45% in patients with organic disease; the sensitivity was 94% and specificity 55%. 
Three or more criteria had a sensitivity of 84% and specificity of 76%
73
. In 
epidemiological studies, the required number of Manning symptoms to fulfil IBS criteria 
has usually been two or three
74-77
. For population studies, a cut off of two Manning 
symptoms have been suggested, because of a lower prevalence of organic diseases in the 
general population than among outpatients
78
.  
In 1989, a multinational committee of clinical-investigators published first Rome 
criteria for IBS diagnosis
79
, originally presented at the Thirteenth International Congress 
of Gastroenterology held in Rome in 1988. IBS was defined as “a functional 
gastrointestinal disorder attributed to the intestines and associated with symptoms of: (a) 
abdominal pain, and/or (b) disturbed defecation, and/or (c) bloatedness or distension”
79
. 
Later, presence of abdominal pain was suggested as a requirement for the diagnosis, but 
the decision to do so was left to the investigator
80
. Terms such as spastic colon or irritable 
colon were no longer recommended. These criteria were revised later and published as the 
Rome I criteria
81
 (Table 1). The main change from the 1989 criteria was the requirement 
of abdominal pain for IBS diagnosis. Rome I criteria consisted of abdominal pain related 
symptoms and non-pain related symptoms, later named the IBS supporting symptoms 
(Table 1).   
The Rome I criteria were again revised, and the Rome II criteria published in 1999 by 
a Working Team
82
. The Rome II criteria were a committee consensus based on research 
results and expert opinion. The development process included reviewing and commenting 
by international experts. In the Rome II criteria, the second part, i.e. non-pain related 
symptoms of the Rome I criteria was deleted, due to poor clustering of these symptoms in 
factor analyses
83,84
, their lower prevalence among males
85
, and their partial inclusion in the 
first, pain-related part of Rome I criteria. In addition, “discomfort” was added to “pain”, 
and symptom duration was extended from three months to 12 months, with abdominal 






(Table 1). Rome I and Rome II criteria have been developed for both clinical practise and 
research purposes, such as epidemiological surveys, pathophysiology research, and 
therapeutic trials.  
In 2006, the Rome II criteria were again revised employing a consensus approach, 
leading up to publication of the Rome III criteria by the Rome Working Team
86
 (Table 1). 
The main change concerned the time perspective: the diagnostic criteria must be fulfilled 
for the last three months instead of 12 months. In addition, symptoms had to have begun at 
least 6 months before clinical presentation addressing the chronic nature of symptoms.  
Despite of wide use of the Rome criteria in research, their accuracy has received little 
study. For Rome I criteria, the sensitivity for detecting IBS was 85% and specificity 71% 
in a study of 602 patients
87
. In a retrospective study, Rome I criteria had a sensitivity of 






IBS can be divided into three subtypes according to predominant bowel habit. In IBS with 
constipation (IBS-C), stools are usually hard or lumpy, and bowel movement frequency is 
less than three per week. Straining during a bowel movement is common. In IBS with 
diarrhoea (IBS-D), stools are usually loose, mushy, or watery and bowel movements take 
place more than three times a day. In addition, urgency (having to rush to bathroom) is a 
common phenomenon. Mixed IBS (IBS-M) applies to subjects expressing both 
constipation and diarrhoea variably, for at least 25% of the bowel movements.
7
 After a 
period of constipation, frequency of bowel movements typically increases leading to a 
period of diarrhoea. Usually these periods fluctuate rapidly within hours or a up to 
week
89,90
. Unsubtyped IBS refers to those not meeting the definition for IBS-C, IBS-D, or 
IBS-M, while Alternating IBS is recommended to define those whose IBS subtype 
changes to another over a longer, more than one year, period of time
89
. 
Each IBS subtype (IBS-D, IBS-C, IBS-M) forms about one third of the patients 
fulfilling the Rome II IBS criteria
89





 in population based studies, however, and also IBS-D has been 
reported to be the commonest subtype
93
. During a three month follow-up, approximately 
half of IBS patients shift from IBS-C or IBS-D to IBS-M, but shifting from IBS-D to 
IBS-C, or vice versa, is less common
94
.  
The Rome II subtyping of IBS is based on non-pain related IBS supporting symptoms, 
while Rome III subtyping is based solely on stool consistency according to the Bristol 
Stool Form, which has shown good correlation with whole-gut transit time
95-98
. The 
validity of IBS subtypes is uncertain. In a comparison study, IBS subtypes defined by 










Table 1. Manning, Rome I, Rome II and Rome III criteria for IBS. 
Manning criteria for IBS (Usually 2 or 3 symptoms required for criteria fulfilment)  
Looser stools at onset of pain 
More frequent bowel movements at onset of pain 
Pain eased after bowel movement 
Visible (abdominal) distension 
Passage of mucus 
Feeling of incomplete evacuation 
 
Rome I criteria for IBS 
At least 3 months continuous or recurrent symptoms of: 
  1. Abdominal pain or discomfort which is: 
Relieved with defecation; and/or 
Associated with a change in frequency of stool; and/or 
Associated with a change in consistency of stool 
And 
  2. Two or more of the following, on at least a quarter of occasions 
      or days: 
Altered stool frequency, 
Altered stool form (lumpy/hard or loose/watery), 
Altered stool passage (straining or urgency, feeling of  
incomplete evacuation) 
Passage of mucus, 
Bloating or feeling of abdominal distension. 
 
Rome II criteria for IBS 
At least 12 weeks or more, which need not be  
consecutive, in the preceding 12 months of abdominal 
discomfort or pain that has two out of three features: 
1. Relieved with defecation; and/or  
2. Onset associated  with a change in frequency of  
  stool; and/or 
3. Onset associated with a change in form  
 (appearance) of stool. 
 
Rome III criteria for IBS* 
Recurrent abdominal pain or discomfort at least three days per month in the last three months 
associated with two or more of the following: 
1. Improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool 










The incidence of IBS shows a substantial variation ranging between 2 to 70 per 1 000 
patient years
100-104
. In Western countries, the prevalence of IBS ranges between 3 and 25% 
of the population
92,103,105
. In non-Western countries, both lower prevalence estimates
106-108
, 
and similar rates to Western countries have been reported
109
.  
 Table 2 shows IBS prevalence in several population studies according to varying 
diagnostic criteria and gender. In general, the Rome II criteria give a lower prevalence 
estimate than the Manning criteria. Some studies have included only two of the six 
Manning symptoms, while others have required three symptoms. The more symptoms 
required, the lower the prevalence estimate of IBS, which partly explains the variation in 
prevalence estimates.  
Sociodemographic factors 
In most studies, female gender is over-represented amongst IBS populations by a ratio of 
1.5 to 2.0
77,100,105,110-114
. Some studies applying the Rome II criteria, however, report a 
female to male ratio closer to one
115-118
. IBS-C is more common among females than 
males, while IBS-D is more common among males
119-122
. Females more often report 
bloating and extraintestinal comorbidity
123
.  
Pain related symptoms (pain eased after bowel movement, pain related to change in 
bowel habits) are equally common in both sexes
84
. Symptoms not related to pain 
(diarrhoea, constipation, bloating, extraintestinal manifestations), however, are more 
common among female patients
85,123
. Inclusion of non-pain related symptoms may partly 
account for female over-representation in IBS by Manning criteria. According to some 
reports, Manning criteria are less reliable in males
124,125
. 
 The prevalence of IBS is highest between 20 to 40 years old
126




Some studies report a decrease in IBS prevalence with increasing income
93,128
, 
suggesting that IBS is more prevalent amongst the lower social class. On the other hand, 








Table 2. Prevalence of IBS by varying diagnostic criteria         
    Response      IBS prevalence 
Study Population Country Method rate (%) n IBS criteria All Male Female 
Talley et al. 1991
78
 Olmsted County; random sample USA Postal survey 82 835 ≥ 3M  12.8 12.1 13.6 
Heaton et al. 1992
77
 Physicians' registry sample UK Postal survey 72 1 896 ≥ 3M  9.5 5.0 13.0 
Jones et al. 1992
110
 Physicians' registry sample UK Postal survey  1 620 ≥ 2 M  21.6 18.7 24.3 
Drossman et al.1993
105
 Random sample of households USA Postal survey 66 5 430 Rome 1989 9.4 7.7 14.5 
Österberg et al. 2000
42
 Random suburban sample Sweden Postal survey 58 2 707 Rome I 10.6 7.4 13.3 
Boyce et al. 2000
75
 Random sample of electoral roll Australia Postal survey 72 2 910 ≥ 2 M  13.6 9.8 17.2 
      Rome I 4.4 2.2 6.4 
      Rome II 6.9 4.6 9.2 
Talley et al. 2001
130
 Birth cohort of young adults New Zealand Questionnaire 86 890 ≥ 2 M  12.7 10.8 14.6 
      Rome II 4.3 3.3 5.3 
Mearin et al. 2001
76
 Random population sample Spain  Personal interview 76 1 932 ≥ 3 M  10.3 5.6 14.8 
      Rome I 12.1 7.2 16.8 
      Rome II 3.3 1.9 4.6 
Bommelaer et al. 2002
131
 Random population sample France Postal survey NR 11 131 Rome I 4.0 2.5 5.3 
Saito et al. 2003
115
 Olmsted County; random sample USA Postal survey 72 643 Rome I 6.8 5.6 8.0 
      Rome II 4.7 4.9 4.5 
Hungin et al. 2003
92
 Random population sample 8 European  Telephone interview NR 41 984 Manning 6.5 NR NR 
  countries    Rome I  4.2 NR NR 
      Rome II 2.9 NR NR 
Dapoigny et al. 2004
132
 Random population sample France 2 phase postal survey 76 and 83 15 120 Rome II 4.7 3.7 5.7 
Wilson et al. 2004
133
 Physicians' registry sample UK 2 phase postal survey 62 and 78 4 807 Rome II 10.5* 6.6* 14.0* 
Andrews et al. 2005
93
 Household sample USA Internet survey 82 25 986 Rome II 6.6 4.7 8.2 
          
≥ 2 M, At least two Manning symptoms         
≥ 3 M, At least three Manning symptoms         
*Including those with a previous IBS diagnosis by physician        






Comorbidity in IBS 
About half of the IBS patients in primary care have at least one comorbid somatic 
symptom, and up to 94% of them have a comorbid psychiatric disorder
134
. The most 
frequently reported symptoms include fibromyalgia, headache, back pain, chronic pelvic 
pain, temporomandibular joint pain, pollacisuria, dyspareunia, heart palpitation, 
depression, anxiety, chronic fatigue syndrome, and somatoformic disorders. Most studies 
assessing comorbidity in IBS have been carried out in clinical settings, i.e. among health 
care users. In a population based study, IBS non-consulters have also demonstrated higher 
rates of psychiatric and somatic comorbidities than population controls
135
.    
Similarities occur in the demographic distributions and psychological profiles among 
IBS and many comorbid conditions, suggesting a possible common underlying 
pathophysiologic mechanism or a common underlying disorder with different 




Depression and anxiety are common societal conditions. In a pan-European study, a 
6-month prevalence rate for depressive disorders was 17%
136
. In the US, the life-time 
prevalence of major depression was 17% in the general population, and 25% had suffered 
an anxiety disorder
137
. In a Finnish population based interview study, the 12-month 
prevalence of a major depressive episode was 9.3%
138
.  
A comorbidity of depression, anxiety, and medical illness is also common. In the 
WHO Collaborative Study, primary health care patients with anxiety disorders were nine 
times more likely to develop depression than those with no other illness. Compared to 
patients with two or more chronic medical conditions, those with anxiety were six times 
more likely to develop depression. In addition, 39% of patients with depression also had 
an anxiety disorder, and 44% of those with an anxiety disorder also had depression.
139
 
Patients with depression often present with overlapping somatic symptoms typically 
including medically unexplained pain
39
. Almost 30% of patients with depression also meet 
the criteria of IBS
140,141
.  
Patients with depression, or anxiety, use more healthcare services than those without. 
Amongst high utilizers of primary healthcare, 24% suffer from major depression, 33% 
have a lifetime history of depression, and 40% generalised anxiety disorder. In total, 83% 
of the high utilizers have psychiatric condition, including panic disorder, at some time in 
their lives.
142
 Amongst patients with somatic medical conditions, the presence of a 




Mental distress and psychiatric symptoms are over-represented in IBS
42
. Common 






disorder, post-traumatic stress disorder, and somatoform disorders including 
hypochondriasis and somatisation disorder
144-146
.  
Depression and anxiety are more prevalent amongst subjects with IBS than population 
controls or patients with somatic gastrointestinal conditions, such as inflammatory bowel 
disease
147
. Depression in IBS patients appears to be more common with females than 
males
148
. In primary care, patients with at least one GI symptom have a four to five fold 
prevalence of severe depression or anxiety compared to patients with no GI symptoms
149
.  
Psychiatric comorbidity may partly account for the higher level of healthcare use 
reported in IBS. Anxiety is particularly associated with healthcare seeking behaviour
108
. 
On the other hand, a strong association between IBS and psychiatric disorders have been 
found independently of healthcare seeking status
150
.  
Somatic comorbidity  
Gastrointestinal comorbidity 
Almost half of the IBS patients also manifest other GI disorders, such as functional 
dyspepsia (FD), GERD, functional constipation, and anal incontinence
151
. The separation 
of IBS, FD, and reflux has been criticised because of the poor clustering of these disorders 
in factor analyses and a strong tendency of subjects in epidemiological studies to flux 
between IBS, FD, reflux, and unspecified GI symptoms. Approximately 50% of subjects 
with GI symptoms such as IBS, functional dyspepsia, or reflux, change their symptom 
profile during a one year follow-up
9
. A possible common underlying mechanism or 
unspecific responses to patophysiological and psychological disturbances have been 
proposed to explain the variety of functional GI symptoms
9
. 
Up to 87% of the subjects with IBS also have FD
9,152
. Among IBS patients in a tertiary 
referral centre, IBS-C shows a higher rate of comorbidity with FD than other subtypes
153
. 




GERD is a common symptom occurring in about 20% of subjects in the general 
population. IBS shows a substantial co-occurrence with GERD, as approximately 40% of 
IBS healthcare seekers also have symptoms of GERD
155
. 
Anal incontinence following first vaginal delivery has more frequently been reported 
(64%) in women with IBS compared to 10% without
156
, possibly related to rectal 
hypersensitivity and hypocompliance, especially in IBS-D
157
.    
IBS has also been associated with a higher rate of abdominal surgery, especially 
subjects with psychiatric comorbidity. For example, cholecystectomy rates for IBS 








Extraintestinal comorbidity  
Several nonpsychiatric extraintestinal symptoms are more prevalent in subjects with IBS 
than amongst non-IBS controls. In a US study, costs due to extraintestinal comorbidity 
covered more than 65% of costs incurred by IBS
158
. The most studied comorbidities are 
fibromyalgia, chronic fatigue syndrome, and chronic pelvic pain, all of which occur in 33 
to 50% of IBS patients
151
.  Population prevalence of fibromyalgia is 2%
159
, chronic fatigue 
syndrome is 0.4%
160
, and chronic pelvic pain occurs in 14% of females
151
.  
Chronic headache, migraine, temporomandibular joint disorder, and back pain are also 
significantly more common amongst IBS patients than healthy controls
151
. Besides chronic 
pelvic pain, other urogenital symptoms, such as dysuria, interstitial cystitis, dysmenorrhea, 
premenstrual syndrome, and disturbances in sexual function have also been reported more 
frequently than expected. Other symptoms include urinary stones, cardiac palpitations, and 
bronchial asthma or hyper-reactivity
161
.  
Many common underlying physiological mechanisms, such as smooth muscle 
disorder, immune dysfunction, inflammatory condition, neuromuscular disease 
accompanied by visceral hypersensitivity, female hormonal alterations, behavioural 
response to pain, alterations in serotonergic system, and psychological factors are possible 
links between IBS and extraintestinal comorbities. A theory of a global disease with 
symptoms covering multiple organs has not been proven to be the case. Multivariate 
analyses show comorbidities of IBS to be diseases of their own rather than a manifestation 
of a single disorder. IBS-sufferers with somatic comorbidities, however, possibly 





The objective of treatment in IBS is to alleviate symptoms and increase QoL. A good 
patient-physician relationship is important for satisfactory treatment. The strength of the 
physician-patient relationship is inversely proportionate to the number of physician visits; 
a positive interaction between the physician and the patient has been associated with a 
reduced use of healthcare services
12,162
. Providing a diagnosis for the patient with an 
explanation of the benign nature of the symptoms will reduce fear of a malignant disease, 
help him or her to cope with the symptoms, and may even reduce the need for 
pharmacological treatment
163-165
. Factors worsening or triggering the symptoms, such as 
psychosocial stress or diet should be reviewed. In primary care, patients often attribute 
their symptoms to stress, but in secondary care are more likely to have psychiatric 
comorbidity, and consider stress unimportant for symptoms
166,167
. Patients seem to expect 
more benefit from advice for diet, lifestyle, and exercise than from drugs
168,169
.  
A total of 60 to 70% of subjects with IBS associate their GI symptoms with food 
sensitivity
170,171
. Dietary triggers reported to exacerbate IBS symptoms include caffeine, 
lactose, alcohol, fatty food, wheat, corn, citrus, food rich in carbohydrates, and hot 
spices
171-173






with IBS-D. A poor correlation, however, exists between reported lactose intolerance and 
a true lactose malabsorption
174,175
. In addition, lactose restriction among subjects with 
IBS, reporting symptom exacerbation after lactose ingestion, does not necessarily improve 
GI symptoms
176,177
. Excess ingestion of fructose has also been associated with 
exacerbation of symptoms and occasionally a restriction diet may prove helpful
178,179
. No 
allergic IgE mediated reaction has been found to explain symptom exacerbation after 
meals
170,180
. Positive findings in some studies exploring the efficacy of food elimination 




Increasing dietary fibre is generally recommended, though proof of efficacy of 
symptom alleviation is limited. Fibre products accelerate stool transit, and they are 
effective for treating constipation in IBS, but not pain or diarrhoea
182,183
. Moreover, 
insoluble fibre, such as wheat bran can even worsen symptoms such as abdominal bloating 
and flatulence
165,184-186
. For global symptom relief in IBS, soluble ispaghula husk seems to 
increase the rate of adequate relief and alleviate symptom severity, but insoluble fibre is 
no more effective than placebo
186-188
. 
Probiotics are live microorganisms capable of exerting health benefits on the host. 
Possible mechanisms of action include modulation of the host immune system, stimulation 
of defensive systems, and competitive decrease in the number of pathogens. Health 
benefits depend probably on the bacterial strain
189
. Bifidobacteria and probiotic 
combinations improve IBS symptoms, particularly flatulence and bloating, while 
lactobacilli alone does not seem efficient
181,190
. Optimal dosage and combination of 
probiotics are unknown at the time.  
Pharmacological treatment  
The drugs available for IBS at the moment have limited evidence of efficacy. Less than 
one quarter of IBS patients demonstrate complete relief of IBS symptoms
92
. In addition, 
side effects of pharmacological therapies may have a considerable negative life impact
191
. 
The placebo effect is particularly strong, up to 70% in IBS drug studies
192
.  Drug treatment 
is targeted to the dominant symptom or symptoms, usually diarrhoea, constipation, 
abdominal pain, or bloating. 
Loperamide, a synthetic opioid, not transversing the blood-brain barrier, is effective in 
the treatment of diarrhoea by reducing stool frequency and improving stool consistency, 




In addition to dietary fibre supplementation and commercial fibre preparations for 
constipation, osmotic laxatives, such as lactulose, or polyethylene glycol (PEG) are 
commonly used, although little studied in IBS. Amongst subjects with functional 
constipation, a low dose PEG may be more effective and produce less flatulence than 
lactulose
197
. Amongst adolescents with IBS-C, treatment with a PEG laxative had a 








Smooth muscle relaxants and anticholinergic antispasmodics improve abdominal pain, 
but evidence of improving global IBS symptoms is not sufficient
181,199,200
. Generally these 
are taken on as-needed basis. Side-effects include dry mouth, dizziness, blurred vision, 
and constipation. Also, peppermint oil may be superior to placebo in alleviating IBS 
symptoms, possibly by relaxing smooth muscle
201,202
.  
Tricyclic antidepressants (TCA) and selective serotonin reuptake inhibitors (SSRI) 
alleviate neuropathic pain
203,204
. In IBS, TCAs have been used for abdominal pain. They 
have both anticholiniergic and non-selective serotonin reuptake actions. The 
neuromodulatory and analgesic features, thought to act by inhibiting visceral 
hypersensitivity, usually appear at lower doses than those used in the treatment of 
depression
36,205,206
. Anticholinergic side effects are similar to those with antispasmodics. 
Daily administration may bring out side effects even with low doses, however, the number 
needed to harm is 22
203
. According to a recent meta-analysis, the number needed to treat 
(NNT) is 4 (95% CI 3 to 8)
207
. A gradual introduction of TCA and a treatment duration of 
6 to 12 months before dose tapering, has been suggested
173
. Patients with IBS-D may 
benefit of TCAs more than other subtypes
208,209
. 
SSRIs have been widely used for treatment of anxiety, depression, and somatisation 
disorders
210
. A few studies have assessed the role of SSRIs in IBS. Paroxetine improves 
QoL and overall well-being without a significant change in pain
211,212
. Fluoxetine may 
alleviate abdominal pain in patients with rectal hypersensitivity
213
, and increase the 
frequency of bowel movements besides relieving pain in IBS-C
214
. According to a 
meta-analysis of five SSRI studies, NNT with SSRIs is 3.5 (95% CI 2 to 14)
207
. 
Alocetron, a 5-HT3 receptor antagonist, has high quality evidence from several studies 
on relieving global IBS symptoms in IBS-D with a NNT of 8. Due to serious side-effects, 
such as ischemic colitis and constipation-related surgery, however, it is not available in the 
EU market. The 5-HT4 partial agonist tegaserod is more efficient than a placebo in 
relieving global IBS symptoms in female patients with IBS-C or IBS-M. The proportion 
of responders is between 5 and 19% higher than with placebo in several studies. Due to a 
ten-fold risk (frequency 0.11%) of cardiovascular events compared to controls, however, 
the drug has been withdrawn from market.
181
















 have been used to treat IBS. In a meta-analysis, the 
NNT of psychological studies was 4 (95% CI 3 to 5). Patients not responding to other IBS 
therapies could possibly benefit of psychological therapies, especially cognitive 
behavioural therapy. Most of the data is derived from small studies, however, and more 









IBS symptoms are one of the most common reasons for physician visits in primary care 
and referrals to gastroenterologists
105,226
. In the US, functional GI disorders, such as 
constipation, dyspepsia, and IBS were among six leading GI physician diagnoses in 
outpatient visits in 2002
227
. Of those with IBS symptoms, 23 to 84% consult a primary 
care physician in a one year period
127,131,228-232
. According to some studies, females are up 
to 3.3 times more prone to seek healthcare for GI symptoms
105,233
, while others have found 
no gender difference in consultation behaviour
77,229,231
.  
Severity and the number of GI symptoms, presence of comorbid conditions, 
psychological factors (such as coping ability), depression or anxiety, and reduced QoL 
have been shown to predict healthcare seeking
77,229,231,234-236
. Those with high levels of 
somatisation are more likely to be referred to secondary and tertiary centres
166
 and they 
also exhibit more psychiatric symptoms and abnormal illness behaviour. In population 
surveys or patients with mild GI symptoms, however, the association of psychiatric 
symptoms and healthcare seeking seems to be weaker
237,238
.   
Besides consultations for GI symptoms, subjects with IBS make 2 to 3 times as many 




In an Italian study, IBS-D was associated with an increased rate of physician visits 
232
. 
In another study from US, however, no difference was detected in healthcare seeking 
behaviour between IBS subgroups
127
. 
Abnormal illness behaviour 
Besides multiple somatic complaints, inappropriate physician consultations for minor 
illnesses have been associated with IBS
241
. Illness behaviour refers to how a person 
perceives abnormal bodily signals, i.e. symptoms of a disease and how he or she acts upon 
them. The decision of consulting a physician depends on knowledge on various symptoms 
and possible diseases behind them, the perceived intensity of symptoms, and individual 
health concerns
235
. In IBS, normal visceral stimuli and bodily sensations can be 
misinterpreted as signs of a disease. Symptom severity, worry of a serious illness, anxiety, 
and depression has been shown to discriminate IBS consulters and non-consulters
242
. Also, 
beliefs about the efficacy of available treatments can influence consultation decisions.  





The healthcare costs of IBS patients are more than 50% higher than controls
243,244
. IBS 
mostly affects working age people leading to productivity loss due to sick leave. In a study 






annual costs varied between 700 and 1 600€ per subject
245
. In a population based study, 
annual direct costs were 860€ per patient in France
246
. Costs incurred by Rome II criteria 
are reported to be higher than those by Rome I
247
. 
The perspective of a cost evaluation may be that of an individual patient, a third-party 
payer (i.e. an insurance company or government), an individual hospital, or the society as 
a whole. In a societal perspective all expenditures are included regardless of the payer. 
Total expenditures consist of direct, indirect, and intangible costs. Direct costs are those 
related to use of healthcare services, medical investigations, and therapy. Indirect costs 
refer to productivity losses due to absenteeism from work and time spent at healthcare 
services. Intangible costs are incurred by pain, suffering, and reduced QoL, factors usually 
not evaluable in monetary terms.  
Direct costs 
In a review of US and UK studies about the economic impact of IBS, direct annual costs 
ranged widely between $348 to $8750 per subject
248
. Comparison between studies is 
difficult because of calculation differences for mean costs per subject. Some authors 
include only those with nonzero charges (i.e. healthcare users)
243
, others divide total costs 
by all participants even including non-healthcare users
246
. In addition, some only report GI 
related costs, while others include all costs irrespective of a particular diagnosis
243
. 
Different healthcare systems may also impede comparison. In a comparison between the 
UK and US, however, the use of healthcare facilities was largely similar despite 
differences in healthcare funding
249
.  
In the US, direct costs of IBS have been estimated at approximately $1.5 billion 
annually. In a comparison of 17 GI diseases in 1998, the highest direct costs were for 
GERD ($9.3 billion), followed by gallbladder disease, colorectal cancer, peptic ulcer, 
diverticular disease, pancreatic disease, non-foodborne diseases, and chronic liver diseases 
before IBS. Pharmaceutical costs were markedly higher for GERD ($5.9 billion) than IBS 
($0.08 billion), accounting for the presence of few effective drugs for IBS. In IBS, office 
visits covered the largest share (17%) of directs costs, but only 6% in GERD.
250
 Also in 
France, office visits formed the largest share of direct costs
246
.  
Hospital inpatient costs for IBS have shown a wide variation between studies. Some 
studies report equal costs for IBS and control groups
158,251
, some higher for IBS
244,252
, 
others lower for IBS group
253
. The share of hospital inpatient costs have ranged between 7 
and 70% of direct IBS costs
254
.  
Diagnostic testing in IBS is performed to seek or rule out possible organic disease 
causing GI symptoms. In the US, almost one quarter of colonoscopies performed on 
patients under age 50, are for IBS symptoms
255
. A linear relationship has been detected 
between levels of somatisation and the amount of diagnostic testing for GI symptoms in 
IBS patients
256
. In a retrospective cohort analysis, colonoscopy or barium enema had been 









Subjects with IBS incur indirect societal costs due to missed work days and impaired work 
performance because of GI symptoms. In a US bank employee study, IBS caused a 
reduction of 21% in work productivity, equivalent to working less than 4 days in a 5-day 
work week
258
.  In another study, at least one third of IBS patients missed 1 working day 
monthly and 46% of them reported impairment at work because of GI symptoms
249
. 
IBS-employees with impaired work performance have more non-GI comorbidities, such as 
fibromyalgia, chronic fatique syndrome, and urinary tract symptoms, than those with 
normal work performance despite IBS
259






3. AIMS OF THE STUDY 
The main objectives of this thesis were: 
 
1. To assess the prevalence of  IBS 
a. To evaluate IBS prevalence according to a variety of IBS definitions and 
diagnostic criteria 
b. To assess the differences in symptom severity and health care use between 
subjects meeting differing IBS criteria 
2. To evaluate the comorbidity in IBS and its impact on health care use 
3. To investigate the connection of depressive and GI symptoms in the general 
population 








4. MATERIALS AND METHODS 
Sample 
The study was a two-phase postal survey (Figure 2). A random sample of 
non-institutionalised persons aged 18 to 64, was drawn from the National Population 
Registry. It comprised 2 490 men and 2 510 women with subjects’ name, address, postal 
code, and age. 
Only subjects, whose mother tongue was Finnish, were sampled. Those living in the 
Ahvenanmaa communal area were not included, as 93% of its inhabitants had Swedish as 
their mother tongue at the time of the study.  
The sample size of 5 000 subjects was based on an assumption of 10% IBS prevalence 
in the population according to previous studies in Western countries, and a response rate 
of 70% (3 500 questionnaires for analysis). This allows subgroup analyses in the IBS 
group to detect a 5 to 10% unit frequency difference of a variable between an IBS group 
and non-IBS group with 5% precision and 90% confidence.  
Questionnaires 
Questionnaire I (Appendix A) 
Questionnaire I, which was sent to a random sample of 5 000 subjects, contained 58 items: 
basic demographics (age, gender, marital status, education, and working hours), presence 
of a variety of somatic conditions diagnosed by a physician (lactose intolerance, celiac 
disease, atopic diseases, or bronchial asthma). In addition, a history of abdominal surgery, 
abdominal pain during childhood, history of upper or lower GI endoscopy, presence of 
any chronic medical condition, and regular medication were inquired (see Appendix A).  
Items covering IBS diagnostic questions and those related to severity of abdominal 
symptoms were translated into Finnish from the Rome II Integrative Questionnaire, 
covering functional GI disorders from oesophagus to anorectum, designed primarily for 
epidemiological surveys
19
. According to the coding instructions, detection of the Rome II 
IBS criteria is based on six items including a question on the frequency of abdominal pain 
(q17), pain improvement with defecation (q20), questions on frequency of bowel 
movements (q21-22) and a change in stool form (q23-24) associated with abdominal pain. 
In addition, the Rome II Questionnaire includes nine items covering IBS supporting 
symptoms: abnormal frequency of bowel movements (q30-31), abnormal form of stools 
(q32-33), feeling of incomplete evacuation (q34), straining during a bowel movement 
(q35), urgency (q36), passage of mucus (q37), and abdominal bloating (q38). These 
symptoms are used to subclassify IBS into constipation-predominant and 
diarrhoea-predominant patterns
19






Manning and Rome I criteria (Table 1). In the Questionnaire I, Manning 2 criteria were 
defined as fulfilment of at least two of the six Manning symptoms and presence of 
abdominal pain more often than one day out of ten during the previous year. In Manning 3 
criteria, at least three Manning symptoms were required. Rome I criteria were defined as a 
combination of abdominal pain more often than one day out of four, pain eased after 
bowel movement or associated with a change in bowel habits, and at least two of the five 
IBS supporting symptoms
81
 (Table 1). Dyspepsia was defined as presence of abdominal 
pain or discomfort (q17), localised in upper abdomen (q27-28), and not relieved with 
defecation (q20-24).   
The response scale for all items to identify IBS and dyspepsia, as well as an item 
assessing the frequency of daily activities disturbed by pain, was a five grade frequency 
scale, which has later been proven to perform better than a binary scale
260
. Answering 
options were: 1) not at all or rarely; 2) occasionally; 3) often; 4) very often; 5) almost 
always. Time scales were defined as follows: Occasionally: more than one tenth of the 
time; Often: more than one quarter of the time; Very Often: more than one half of the 
time
19
. The severity of abdominal pain and discomfort during the previous year was 
assessed by the 4-grade Likert scale (mild, moderate, severe, and very severe). 
The items translated into Finnish were then back-translated into English by an 
American-English translator. The back-translated items were compared with the original 
ones. Minor differences were noticed in the choice and order of words; such as “not at all 
or rarely” in the original was turned into “seldom or never” in the cross-translation. The 
cut-off points (choices such as “often”) in the frequency scale were identical in both 
questionnaires, however, suggesting that translation of the questionnaire into Finnish 
would not affect the number of IBS subjects identified.  
Response options for questions covering the number of physician visits for GI and 
non-GI symptoms during the previous year were: 1) none; 2) one to two times; 3) three to 
five times; 4) six to ten times; 5) more than ten times. To approximate the average number 
of physician visits, they were later recoded as: 0, 1.5, 4, 8, and 11. Sick leave days during 
the previous year were assessed by five choices: 1) none; 2) one to three days; 3) four to 
six days; 4) seven to twenty days; 5) more than twenty days; 6) not employed. To 
approximate the mean number of sick leave days, these choices were recoded as: 0, 2, 5, 
10, and 22.  
Frequency of taking prescription medication and over-the-counter medication for GI 
symptoms was assessed by five options: 1) not at all; 2) less than once a month; 3) on 
average one to three times a month; 4) on average one to three times a week; 5) daily or 
almost daily.  
Frequency of headaches and back pain were inquired by four options: 1) less than once 
a month; 2) on average one to three times a month; 3) on average one to three times a 
week; 4) daily or almost daily. 
The final section of Questionnaire I consisted of a Finnish version of the 13-item 
Beck’s Depression Inventory Short Form (BDI-SF)
261-264
. The Finnish version 
(R-BDI-SF) includes 14 items: 13 for depressive symptoms and 1 for anxiety. It has been 
applied in population screening among Finnish adults and adolescents
265,266
 and has shown 








score ranges from 0 to 36. Depressive symptoms are graded as mild (score 5-7), moderate 
(score 8-15), or severe (score 16 or more). Anxiety is scored as mild (score 1), moderate 




To assess the acceptability and item selection of the seven-page Questionnaire I, we 
conducted a pilot study in August 2001. The questionnaire with an explanatory letter was 
given to 30 consecutive outpatients (17 women, 13 men) visiting a gastroenterologist in 
the Department of Gastroenterology, Helsinki University Central Hospital. The patients 
displayed a variety of gastrointestinal disorders: functional GI disorders, inflammatory 
bowel diseases, and hepatic diseases. They were asked to fill in the questionnaire in the 
waiting room before or after the doctor´s appointment and were encouraged to give 
comments on the questionnaire regarding the amount of items, contents of the questions, 
understanding of the questions, and suggestions for improving the questionnaire. 
Twenty-five patients returned the questionnaire. Completion of the questionnaire took 
approximately 12 minutes, which was regarded as a reasonable time by the patients. The 
questions were generally regarded as comprehensible and no changes were made to the 
questionnaire after the pilot study.  
Questionnaire II (Appendix B) 
Questionnaire II, which was sent to those fulfilling IBS criteria in Questionnaire I, 
included detailed questions on the duration of GI symptoms, the most bothersome 
symptoms, and location of abdominal pain. GI-related healthcare use was assessed by 
questions on the number of physician visits at various levels of healthcare organisation 
(primary care, occupational health care, secondary care, emergency room, private sector). 
In addition, the number of upper GI endoscopies, colonoscopies, barium enema, and 
abdominal ultrasound ever performed, were inquired, as well as consumption of 
medication for GI symptoms within nine pharmacological groups (antacids, 
histamine-2-receptor blockers, proton-pump inhibitors, pain killers [including 
non-steroidal anti-inflammatory drugs and paracetamol], antidiarrhoeals, laxatives, fibre 
products, antispasmodics, and prokinetics) during the previous three months. In addition, 
family history of inflammatory bowel disease, colorectal cancer, and celiac disease was 
inquired, (see Appendix B).  
The number of physician visits during the previous year was inquired by six options: 
1) none; 2) once; 3) twice; 4) three times; 5) four to six times; 6) more than six times. To 
approximate the average number of visits, “four to six times” was recoded as “five”, and 
“more than six times” as “seven”.  
For use of medication, the answering options were: 1) not at all; 2) less than twice a 






week; 6) daily or almost daily. To approximate the mean monthly use of medication these 
options were recoded as 0; 1; 2.5; 6; 16, and 24.  
The final part of the Questionnaire II consisted of a validated Finnish version of the 
RAND 36-Item Health Survey 1.0, a generic health-related QoL measurement tool
268
. 
For estimating the direct and indirect IBS costs, a societal perspective was obtained, 
i.e. all costs were taken into account regardless of the payer. Direct costs included those 
for physician visits, transportations, GI endoscopies, and medication. Indirect costs 
included expenses due to sick leave and time costs of physician visits and endoscopies. 
The unit costs for physician visits, transportation, and time costs were derived from the 
National Research and Development Centre for Welfare and Health
269
.  Costs of GI 
endoscopies were calculated as average prices between five university hospital districts of 
Finland. Medication costs were calculated based on a defined daily dose weighted with 
unit sales records within the ATC-4 group. Retail prices without VAT were derived from 
pharmacist price lists. Sick leave expenses, applying the human capital method
270
, were 




Questionnaire I was sent on the 18
th
 of September 2001. The first reminder for 
non-respondents was sent on the 30
th
 of October, and the final reminder on the 12
th
 of 
December 2001.   
Questionnaire II was sent to 591 subjects who met IBS criteria either by Manning ≥ 2 
symptoms, or Rome II criteria in Questionnaire I. First mailing was on the 20
th
 of 
February 2002. For non-responders, two reminders were sent 6 weeks apart.  
All returned questionnaires were optically scanned and the data transformed into an 
Excel form. Statistical analyses were performed with NCSS-2000 software for Windows 
(NCSS Statistical Software, Kaysville, UT) and SPSS 13 software for Windows (SPSS, 
Inc, Chicago, IL, USA).  
Control groups 
In study I, four partially overlapping IBS groups were formed (Manning 2, Manning 3, 
Rome I, and Rome II). Non-IBS controls were subjects who did not meet the IBS criterion 
in question regardless of the possible reporting of GI symptoms and meeting another of 
the four IBS criteria.  
In study II, IBS was defined as those fulfilling the Rome II IBS criteria. The control 
group included all subjects not meeting Rome II criteria.  
In study III, frequencies of GI symptoms were compared between subjects reporting 
depressive symptoms and non-depressive controls. The control group was defined as 






In study IV, IBS related costs were compared between subjects fulfilling Rome II 
criteria and Manning 2 criteria. The control group consisted of those subjects fulfilling 
neither Rome II nor Manning 2 criteria.  
Statistical methods 
Prevalence figures for categorical variables were calculated with 95% confidence intervals 
(CI). Due to overlap of the four IBS criteria, 95% CIs were applied for comparison of 
frequencies of binary variables between the groups. Differences were considered 
statistically significant, if their 95% CIs did not overlap. Direct adjustment against Finnish 
population aged 18 to 64 was applied for age and gender adjustment of the prevalence 
figures by various IBS criteria and depressive symptoms. 
In study I, concordance between different diagnostic criteria was calculated applying 
kappa-statistics (κ). A κ-value of 0.0 to 0.2 indicates slight agreement, 0.2 to 0.4 fair 
agreement, 0.4 to 0.6 moderate agreement, 0.6 to 0.8 substantial agreement, and a κ-value 
of 0.8 to 1.0 near perfect agreement
272
. 
Several variables with multiple categories, such as marital status, basic education, 
working hours, depression score, and anxiety, were dichotomized for comparison. The 
chi-square test was applied for categorical and T-test for dimensional variables. In study 
II, the Bonferroni correction for multiple testing was applied.  For nonparametric 
comparison of medians, the Mann-Whitney’s U-test was applied between two-group 
testing, and Kruskall Wallis test between three groups.       
In study II, the distribution of comorbid conditions was compared between GI 
consulters and non-consulters among IBS group and controls. GI-consulters referred to 
those with at least one physician visit for GI symptoms during the previous year. A 
loglinear model was applied for comparison of categorical variables, and a two-way 
analysis of variance for continuous variables. To detect independent predictors of 
healthcare seeking for GI and non-GI reasons, a stepwise logistic regression analysis was 
performed with 26 variables: fixed variables (IBS, age, gender, basic education), working 
hours, employment status, marital status, GI conditions (dyspepsia, diarrhoea, 
constipation, severe abdominal pain, disturbance of daily activities because of GI 
symptoms, lactose intolerance, celiac disease, history of abdominal pain during childhood, 
history of abdominal surgery), allergic conditions (asthma, food allergy, allergic 
dermatitis, allergic rhinitis), other extra-GI conditions (headache, back pain, chronic 
medical condition), and psychiatric conditions (depression, anxiety and insomnia). In 
addition, interaction variables of each comorbid condition and IBS were generated and 
included in the regression model. For non-GI reasons, a majority of subjects in both the 
IBS and control groups had made at least one consultation during the previous year. 
Therefore, a consulter was defined as a subject with at least three non-GI visits.    
In study III, independent factors associated with depressive symptoms were generated 
with a stepwise logistic regression analysis. Altogether 14 variables were included in the 






chronic medical condition, anxiety, IBS, dyspepsia, diarrhoea, constipation, frequent 
abdominal pain, and history of abdominal surgery.  
In study IV, the non-parametric bootstrap technique
273
 was applied for comparison of 
the skewed cost data. The number of bootstrap replications was 10 000 and 95% 
confidence intervals were constructed by bootstrap percentile method where the lower and 
upper limits of the confidence interval are the 0.025 and 0.975 quantiles of the bootstrap 
distribution. The p-values for the differences between means were constructed by a 
randomisation test. The number of permutations in the tests was 10 000.  
All p-values calculated were two-tailed. A p-value of less than 0.05 was considered 
statistically significant.  
Ethics 
The Ethics Committee of the Helsinki University Hospital evaluated the study protocol 
and stated that no ethical considerations by the committee are needed as the study is a 







For Questionnaire I, 5 000 letters were sent. Due to unknown addresses, 22 were returned. 
After two reminders, a total of 3 631 subjects participated in the study by returning the 
Questionnaire. A total of 20 questionnaires were returned unfilled. Questionnaire II was 
sent to 591 subjects fulfilling the Manning or Rome II IBS criteria in Questionnaire I. Of 
Phase II questionnaires, 8 went to unknown addresses. Altogether 499 filled and two 
unfilled questionnaires were returned (Figure 2).  
The overall response rate for Questionnaire I was 73%. It was higher among females 
than males (79% vs. 67%).  Mean respondent age was 42.1 years (95% CI 41.6-42.5), and 
non-respondents 38.7 years (95% CI 37.3-39.0). Of respondents, 55% were females 
(female to male ratio 1.2:1), whereas 39% of non-respondents were females. Among both 
male and female respondents, the youngest age group (18-24 years) was under-represented 
and oldest age group (55-64 years) over-represented (Table 2).  
For Questionnaire II, the overall response rate was 86% (n=501). No gender difference 
emerged in any of the age groups. Mean respondent and non-respondent age was 42.2 
(95% CI 41.1-43.4) and 37.4 (95% CI 35.0-40.0) years. The proportion of females among 




Table 2. Response rate (%)             
Age 
(years) Questionnaire I   Questionnaire II   
 Male Female Total p* Male Female Total p* 
 n=1 639 n=1 991 n=3 631  n=179 n=322 n=501  
18-24 53.5 73.5 63.3 <0.000 81.0 88.0 85.9 0.436 
25-34 67.1 76.2 71.6 0.002 82.5 77.9 79.5 0.338 
35-44 62.6 78.7 70.6 <0.000 76.0 84.8 81.7 0.196 
45-54 69.5 79.5 74.6 <0.000 94.7 87.4 90.3 0.144 
55-65 81.1 85.0 83.1 0.124 94.9 91.4 92.7 0.509 
Total 67.0 78.9 72.9 <0.000 86.5 85.6 85.9 0.781 
*Male vs. female        
n = number of respondents       












































Figure 2. Flow chart of the study. Manning 2, at least two Manning symptoms; 
Manning 3, at least three Manning symptoms.   
IBS criteria 
fullfilled 
 n = 600 
No IBS 
n = 3 031 
     Manning 2 
n = 587 
     Manning 3 
n = 353 
Rome I  
n = 204 
Rome II  
n = 184 
Manning 2 
n = 586 
Rome II 
n = 184 
Returned n = 496 
 Filled n = 494 
 Empty n = 2 
 
Not returned n = 90  
 Unknown address n = 8 
 Nonrespondent n = 82  
 
n=587 
Returned n = 3 631   
 Filled n = 3 611 
 Empty n = 20 
Not returned n = 1 369  
 Unknown address  n = 22 
 Nonrespondent n = 1 347 
 
n=587 
   Questionnaire II posted 
          n = 591 
Returned n = 159 
 Filled n = 158 
 Empty n = 1 
 
Not returned n = 25  
 Unknown address n = 2 
 Nonrespondent n = 23  
 
n=587 
Questionnaire I posted 






Prevalence of IBS (I) 
At least one of the four IBS criteria was met by 600 subjects, which accounted for 16.5% 
of the respondents. The female to male ratio was 1.8:1. Manning 2 criteria represented the 
broadest IBS definition with a crude prevalence of 16.2% (95% CI 15.0-17.4%). After 
adjusting for age and gender, the prevalence was 15.9% (95% CI 14.7-17.1%). The most 
stringent criteria were Rome II, with a total of 184 respondents. Crude IBS prevalence was 
5.1% (95% CI 4.4-5.8%). After adjusting for age and gender, the prevalence figure 
remained the same.   
A significant gender difference appeared in both the Manning 2 and Manning 3 
groups, with female to male ratio of 1.5:1 and 1.4:1, respectively. In Rome I and Rome II 
groups, no gender difference was evident (Table 3).  
 
 









(n=184)       
Crude           
   Total 16.2 (15.0-17.4) 9.7 (8.8-10.7) 5.5 (4.8-6.3) 5.1 (4.4-5.8)       
   Male 13.1 (11.4-14.8) 8.3 (7.0-9.7) 5.1 (4.0-6.2) 5.1 (4.0-6.2)       
   Female 19.2 (17.4-20.9) 11.2 (9.8-12.6) 6.1 (5.0-7.2) 5.3 (4.3-6.3)       
Adjusted           
   Total 15.9 (14.7-17.1) 9.6 (8.6-10.6) 5.6 (4.8-6.4) 5.1 (4.4-5.8)       
   Male 12.8 (11.1-14.4) 8.1 (6.7-9.5) 4.9 (3.8-6.0) 4.9 (3.8-6.0)       
   Female 19.1 (17.3-20.9) 11.2 (9.8-12.6) 6.2 (5.1-7.3) 5.2 (4.2-6.2)       
           
 
In Manning 2 and 3 groups, the prevalence of IBS showed a declining tendency, 
although not statistically significant, from age 35 upwards (Table 4).  
 
 
Table 4. Fulfillment of varying IBS criteria according to age (%, 95% CI).  
 Manning2 Manning3 Rome I Rome II 
  (n=587) (n=353) (n=201) (n=184) 
Age 18-24 (n=416) 17.8 (14.1-21.5) 10.3 (7.4-13.3) 6.0 (3.9-8.8) 5.3 (3.3-7.9) 
Age 25-34 (n=683) 17.4 (14.6-20.3) 10.5 (8.2-12.8) 5.3 (3.7-7.2) 5.3 (3.7-7.2) 
Age 35-44 (n=837) 16.7 (14.2-19.3) 9.7 (7.8-11.9) 5.6 (4.2-7.4) 4.9 (3.5-6.6) 
Age 45-54 (n=941) 15.4 (13.1-17.7) 9.8 (8.0-11.9) 5.7 (4.3-7.4) 4.8 (3.5-6.3) 
Age 55-65 (n=753) 14.5 (12.0-17.0) 8.6 (6.7-10.9) 5.6 (4.1-7.5) 5.3 (3.8-7.2) 









The mean age for those fulfilling an IBS criterion did not differ from those not 
fulfilling. In addition, no difference was detected regarding marital status. In both 
Manning groups, a lower proportion of subjects had primary school or less as their basic 
education compared to those not fulfilling Manning criteria. No differences in basic 
education appeared in the Rome groups. In the Manning 3 group, a larger share had 
irregular working hours than those not fulfilling Manning 3 criteria.  
Regardless of criteria applied, the diarrhoea-predominant subtype was the most 
common covering 41 to 57% of subjects fulfilling any IBS criterion. The proportion of 
constipation-predominant subtype ranged between 16 and 27%. In Rome II group, 
frequency of constipation did not differ from that of the total sample (Table 6.) 
Overlap of IBS criteria (I) 
A substantial overlap between various IBS criteria was detected. Manning 2 criteria was 
met by 97% of those fulfilling Rome II criteria. Only four subjects (2.2%) in the Rome II 
group exclusively met Rome II criteria (Table 5). Manning 2 criteria showed a substantial 
agreement with Rome I and Rome II criteria, with kappa-values of 0.45 and 0.42. 
Manning 3 criteria’s agreement with Rome I and Rome II was slightly better, kappa-
values were 0.53 and 0.52. A substantial agreement (kappa-value 0.78) was detected 
between Rome I and Rome II criteria.   
 
 
Table 5. Overlap between diagnostic criteria. Number and percentage    
of subjects in column group also meeting upper row criteria.       
          Only   
 M2   M3   RI   RII   Column criteria  
  n % n % n % n % n %  
M2 587 100 0 0 195 33 179 30 183 31  
M3 0 0 353 100 157 44 149 42 182 52  
RI 195 96 157 77 204 100 153 75 8 4  
RII 179 97 149 81 153 83 184 100 4 2.2  






Table 6. Sociodemographic and symptom charasteristics of  total sample and each IBS criterion         
 Total sample Manning2  Manning3  Rome I  Rome II  
  (n = 3 631) (n = 587) p† (n = 353) p† (n = 204) p† (n = 184) p† 
Gender, n (%)   p1**  p1*  p1 = 0.108  p1 = 0.640 
   Male 1 639 (45.2) 209 (35.6)  132 (37.4)  81 (39.7)  80 (43.5)  
   Female 1 991 (54.8) 378 (64.4)  221 (62.6)  123 (60.3)  104 (56.5)  
Mean age, years (SD) 42.3 (12.8) 41.4 (12.9) 0.066 41.5 (12.7) 0.239 42.5 (12.9) 0.844 42.2 (13.1) 0.888 
Marital status, n (%)          
   Married or common law marriage 2 411 (67.1) 398 (67.8) 0.686 248 (68.6) 0.536 138 (67.6) 0.860 120 (65.2) 0.580 
Basic education, n (%)          
   Primary school or less 863 (24.1) 112 (19.2) * 67 (19.1) 0.020 48 (23.6) 0.867 40 (22.0) 0.486 
   High school graduate 1 182 (33.1) 192 (32.9) 0.921 119 (33.9) 0.722 55 (27.1) 0.063 50 (27.5) 0.100 
Irregular working hours, n (%) 751 (21.2) 138 (24.0) 0.074 90 (26.1) 0.019 53 (26.6) 0.053 45 (25.1) 0.183 
Diarrhoea, n (%) 521 (14.3) 242 (41.2) ** 168 (47.6) ** 110 (53.9) ** 104 (56.5) ** 
Constipation, n (%) 548 (15.1) 133 (22.7) ** 66 (18.7) 0.046 54 (26.5) ** 30 (16.3) 0.63736 
Dyspeptic symptoms, n (%) 288 (7.9) 172 (29.3) ** 107 (30.3) ** 98 (48.0) ** 83 (45.1) ** 
Lactose intolerance, n (%) 344 (9.6) 129 (22.2) ** 70 (19.9) ** 53 (26.1) ** 44 (24.3) ** 
Abdominal pain in childhood, n (%) 393 (11.1) 137 (23.8) ** 89 (25.8) ** 68 (34.0) ** 61 (33.3) ** 
Allergic condition, n (%) 626 (18.1) 128 (23.0) ** 83 (24.6) * 40 (20.8) 0.314 43 (24.9) 0.018 
Asthma, n (%) 122 (3.5) 33 (5.8) 0.001 22 (6.4) 0.002 10 (5.0) 0.224 14 (7.8) 0.001 
Headache, n (%) 370 (10.3) 123 (21.0) ** 82 (23.3) ** 54 (26.6) ** 50 (27.3) ** 
Back pain, n (%) 568 (15.9) 173 (29.6) ** 113 (32.2) ** 80 (39.6) ** 64 (35.0) ** 
Depressive symptoms, n (%) 602 (17.0) 175 (30.5) ** 120 (34.8) ** 84 (42.9) ** 70 (39.3) ** 
Anxiety, n (%) 817 (22.8) 229 (39.4) ** 139 (39.6) ** 92 (45.3) ** 77 (42.1) ** 
Insomnia, n (%) 630 (17.5) 155 (26.5) ** 98 (27.8) ** 66 (32.4) ** 59 (32.1) ** 
†p-value vs. those not meeting the criterion         
p1-value male vs. female          
* < 0.01          







GI symptom severity (I) 
Presence of severe or very severe abdominal pain was reported by 44% (95% CI 36.6-
51.1), 45% (95% CI 38.0-51.9), 30% (95% CI 25.2-34.8), and 27% (95% CI 23.7-30.9) of 
subjects in Rome II, Rome I, Manning 3, and Manning 2 groups. Daily activities were 
disturbed by abdominal pain often or very often by 64% (95% CI 57.2-71.1), 65% (95% 
CI 58.5-71.6), 33% (95% CI 27.9-37.7), and 29% (95% CI 25.3-32.6) of subjects in Rome 
II, Rome I, Manning 3, and Manning 2 groups (see Study I, Figure 2). 
Prevalence of depressive symptoms (III) 
According to R-BDI-SF, a total of 602 participants reported depressive symptoms 
corresponding to 17.0% (95% CI 15.7-18.2%) of the total sample, with no gender 
difference. Due to incompletely filled R-BDI-SF, depression score could not be rated for 
82 subjects, who were excluded from the analysis. After age and gender adjustment, the 
prevalence of depressive symptoms was 16.7% (95% CI 15.4-17.9%). Independent 
predictors of depressive symptoms were anxiety, frequent abdominal pain (pain more 
often than 1 day of 4), diarrhoea, constipation, and a chronic medical condition. Higher 
basic education and marriage or cohabiting with a partner protected against depressive 
symptoms (see Study III, Table 2).  
 Of subjects with depressive symptoms, 11.6% (95% CI 9.1-14.2%) fulfilled Rome II 
IBS criteria, compared to only 3.7% (95% CI 3.0-4.4%) of the non-depressive control 
subjects. In addition, diarrhoea, constipation, and dyspepsia rates were higher amongst 
subjects with depressive symptoms.  
Comorbidity in IBS (I,II) 
Rates of dyspeptic symptoms, lactose intolerance, headache, back pain, depression, 
anxiety, and insomnia were higher for subjects meeting any IBS criterion than for 
controls. In addition, they had more often experienced abdominal pain during childhood.  
Presence of asthma or an allergic condition (food allergy, allergic dermatitis, or allergic 
rhinitis) was reported more often than controls in both Manning groups and the Rome II 
group, but no excess rates were reported in the Rome I group (Table 6). 
Prevalence of depressive symptoms (depression score 5 or more according to 
R-BDI-SF) in the Rome II, Rome I, Manning 3, and Manning 2 groups was 39% (95% CI 
32.1-46.5%), 43% (95% CI 35.9-49.8%), 35% (95% CI 29.8-39.8%), and 31% (95% CI 






than the Manning 2 group. In addition, anxiety and insomnia were more common amongst 
those meeting an IBS criterion than those not meeting it (Table 6). 
Healthcare use (I,II,IV) 
During the previous year, a higher proportion of subjects fulfilling any IBS criterion had 
made physician visits for both GI and non-GI symptoms than the total sample. Compared 
to subjects fulfilling either of the Manning criteria, a larger proportion of those fulfilling 
either of the Rome criteria reported visiting physicians for GI symptom (Figure 3). No 
difference emerged in non-GI visits between IBS groups.  
The mean number of GI visits was 0.8 (95% CI 0.7-0.9) and 1.5 (95% CI 1.1-1.8) in 
the Manning 2 and in Rome II groups. In the control group (those fulfilling neither Rome 
II nor Manning 2 criteria), subjects reported on average 0.23 (95% CI 0.20-0.26) GI visits 
during the previous year. For non-GI visits, subjects in the Manning 2 group reported on 
average 3.0 visits (95% CI 2.7-3.2) and those in the Rome II group 3.2 visits (95% CI 2.8-
3.6).  Subjects in the control group reported on average 2.3 (95% CI 2.2-2.3) non-GI visits 



















































Figure 3. Visits to physicians for GI and non-GI reasons during the previous year. 
Predictors of healthcare seeking (II, III) 
In study II we compared subjects fulfilling Rome II IBS criteria to controls. In the control 
group, rates of lactose intolerance, diarrhoea, food allergy and headache were higher 
among GI consulters (those with at least one physician visit for GI reasons) than among 
non-consulters. However, in the Rome II group, rates of these conditions were lower 
among GI consulters (see Study II, Table 1). In addition, in the control group, rates of 






depressive symptoms and anxiety were higher for GI consulters, but no difference 
emerged in the Rome II group between GI consulters and non-consulters.  
When comparing the rates of dyspepsia, extra-GI somatic symptoms (headache, back 
pain, allergic conditions), or psychiatric symptoms (depression, anxiety, insomnia) 
between GI consulters and non-consulters in the Rome II group, only dyspepsia was more 




Figure 4. Rates of comorbid symptoms in Rome II group between GI consulters and non-
consulters. 
 
In the logistic regression analysis, the strongest independent predictors of GI visits 
were GI symptoms, such as disturbing abdominal symptoms (OR 4.06, 95% CI 2.74-
6.01), severe abdominal pain (OR 2.56, 95% CI 1.74-3.79), and dyspeptic symptoms (OR 
2.30, 95% CI 1.62-3.27). Of the non-GI symptoms in the regression model, only insomnia 
(OR 1.57, 95% CI 1.21-2.06), headache (OR 1.43, 95% CI 1.04-1.97), and chronic illness 
(1.39, 95% CI 1.08-1.78) predicted healthcare seeking for GI symptoms. Co-occurrence of 
IBS and the variables in the regression model did not increase the probability of 
consulting a physician.  
 Presence of chronic illness (OR 3.16, 95% CI 2.62-3.82), back pain (OR 2.01, 95% CI 
1.61-2.51), and depressive symptoms (OR 1.79, 95% CI 1.37-2.10) were the strongest 
predictors of non-GI visits. Of the GI symptoms in the regression model, only presence of 
dyspeptic symptoms (OR 1.64, 95% CI 1.20-2.25) and a history of abdominal pain in 
childhood (OR 1.39, 95% CI 1.07-1.81), but not IBS, predicted non-GI visits (see study II, 






Depressive symptoms and health care seeking for GI reasons  
In study III, GI related health care use was compared between subjects with depressive 
symptoms and non-depressive controls. At least one visit for GI reasons during the 
previous year was reported by 24% compared to 13% of controls (p < 0.0001). In addition, 
18% of subjects with depressiveness had sick leave because of GI symptoms compared to 
9% of controls (p < 0.0001).     
Societal costs (IV) 
In study IV, annual societal costs were compared between subjects fulfilling Manning 2 
and Rome II criteria. Total GI related costs per subject were higher in the Rome II group 
(497€, 95% CI 382-621€) than in the Manning 2 group (295€, 95% CI 246-347€, 
p < 0.001). When allowing for population prevalences according to each criterion, the 
nationwide annual GI related costs were higher by Manning criteria than by Rome II 
criteria (154M€, 95% CI 128-181M€ vs. 82M€, 95% CI 63-103M€).  
Direct costs covered two thirds of the total GI costs. The single most expensive cost 
component was the share of physician visits, accounting for approximately 60 % (59% to 
63%) of the direct costs and 40 % (40% to 42%) of the total GI related costs in IBS. The 




























   
Subjects fulfilling either IBS criteria more often used GI medication than controls. The 
share of medications was 13% to 14% of the total GI costs.   Acid controlling medication 
formed 74% to 78% of the drug costs. Of medications for lower GI symptoms, bulking 
agents incurred the highest expense, which was, however, only 5% to 7% of the drug 






expenses. Medication expenses per subject were higher in the Rome II group (63€, 95% 
CI 44-86€) than in the Manning 2 group (42€, 95% CI 33-52€, p < 0.001).  In the 
Manning 2 group, total drug expenses per subject were slightly higher among females than 
males (see study IV, Table 3).  
Annual direct costs of GI endoscopies per subject were 40€ (95% CI 30-50€) in the 
Manning 2 group and 58€ (95% CI 39-81€) in the Rome II group (p < 0.001), with no 
gender difference. At least one colonoscopy was in the history of 46% (95% CI 38.0-53.7) 
of the subjects in the Rome II group and 32% (95% CI 28.0-36.4) in the Manning 2 group. 
For those with at least one colonoscopy performed, the average number of procedures was 
1.6 (95% CI 1.3-1.8) in the Rome II group and 1.5 (95% CI 1.4-1.7) in the Manning 2 
group.  
For non-GI visits, the direct individual costs were 242€ (95% CI 223-260€), 262€ 
(95% CI 228-296€), and 184€ (95% CI 177-190€) in the Manning 2, Rome II, and control 
groups. Nationally, the direct non-GI visit costs amounted to 126M€ by Manning, and 
43M€ by Rome II criteria. Direct GI and non-GI expenditures altogether ranged between 
98 M€ by Rome II and 230 M€ by Manning criteria. 
The average number of sick leave days per subject for GI symptoms was 0.9 (95% CI 
0.7-1.2) and 1.8 (95% CI 1.0-2.6) in the Manning 2 and Rome II groups, while controls 
reported on average 0.3 (95% CI 0.2-0.4) days off work. No gender difference was evident 
in any group. Individual costs of these days were higher in the Rome II group (147€, 95% 
CI 88-214€) than in the Manning 2 group (82€, 95% CI 60-107€, p < 0.001), (see study 
IV, Table 4).   
GI related costs were also assessed by duration of GI symptoms by three categories: 
symptom duration of less than three years, three to ten years, and more than ten years. No 
difference was detected in direct or indirect GI related costs between subjects with 










The prevalence of IBS shows substantial variation depending on the applied diagnostic 
criteria. Of the four IBS criteria studied, both Rome criteria are more stringent than the 
older Manning criteria and they indentify an IBS population with more severe GI 
symptoms and more use of health care resources than those identified by the Manning 
criteria. IBS imposes a considerable burden for IBS sufferers and society. It is associated 
with high rates of psychiatric and somatic comorbidity and healthcare use for both GI and 
non-GI reasons. High population prevalence of IBS and increased use of healthcare 
resources incur high societal costs. Annually, individual GI related costs are almost twice 
as high by Rome II as Manning 2 criteria. Manning 2 criteria, however, identifies a three 
times larger IBS group owing to almost double the total societal GI related costs in 
Finland compared to Rome II criteria.  
Methodological aspects 
Our study was a large scale population based survey with high response rates lending 
support to the findings. A population based approach enables inclusion of subjects not 
using healthcare services. The Rome II Integrative Questionnaire is designed for 
epidemiological surveys, and R-BDI –SF, validated in Finnish
267
, has been widely used in 
surveys for detecting depressive symptoms.   
As the Rome II Questionnaire was not available in Finnish, we translated the items 
used in our study. Translation may produce a source bias as the meaning of some 
expressions may differ between languages and cultures. Back-translation of the 
Questionnaire did not, however, reveal such biases suggesting that the translation process 
did not affect the number of identified IBS subjects.  
For Questionnaire I, females were more prone to respond and consequently female to 
male ratio in the final data was 1.22:1, while at the time of the study, the ratio was 0.98:1 
among Finnish inhabitants of age 18 to 64 years. Although the response rate was good 
overall, only 53.5% of males in the youngest age group responded possibly biasing results 
concerning them. The responders were on average 3.4 years older than non-responders 
which probably does not affect the results as the difference is considerably small and the 
total costs in the study were not higher for subjects in the oldest age groups.  
No formal diagnoses of IBS or depression were confirmed by a physician as the study 
was a postal survey. Therefore, it is possible that some subjects fulfilling IBS criteria had 
an organic disease explaining GI symptoms. In the general population, however, 
functional bowel disorders are much more prevalent than organic diseases causing 
IBS-like symptoms
9
. Therefore, we assume that the IBS prevalence rates detected by our 
questionnaire are not significantly biased by organic diseases in the population. Although 
the BDI-SF is a self-reported depression symptom-rating scale and cannot substitute a 
diagnostic interview, it has shown a good correlation with moderate and severe depression 
in medical in-patients
274






In Questionnaire I, the average number of physician visits and work absenteeism days 
due to GI symptoms were estimated based on five-scale categorised items, which may bias 
the cost estimation of non-GI visits and the number of sick leave days. In Questionnaire II, 
the six-scale categorised items on GI visits offer more exact data as only three subjects in 
the Manning group and two in the Rome II group reported more than six GI visits. 
Comparison of IBS criteria      
In previous literature, the comparison of prevalence estimates and economic burden of 
IBS between individual countries and studies has been hampered by differences in IBS 
definition and criteria. In addition, composition of study population, research 
methodology, and sampling methods vary between studies. In our study, a substantial 
variation in the prevalence rates of IBS was seen depending on the applied diagnostic 
criteria, in line with two previous studies applying various IBS criteria on a population 
sample
75,76
. Even when applying the same study methodology across eight European 
countries, however, a two-fold variation has been detected in IBS rates suggesting that 
true prevalence variations exist between individual countries, associated possibly with 
cultural and dietary habits
92
.  
 In this study, a three-fold difference in IBS prevalence rates was detected between the 
four IBS criteria. Manning 2 criteria were the most liberal and Rome II the most stringent. 
Two previous studies comparing Manning 2 and Rome II criteria obtained two to three-
fold prevalence figures, in line with our results
75,130
. In a systematic review targeting US 
population based studies applying only Rome definitions, IBS prevalence was in the same 




In our study, almost all subjects fulfilling Rome II criteria also fulfilled Manning 2 
criteria. They formed a virtual subgroup of Manning 2 group with more severe abdominal 
pain, more disturbances of daily activities from symptoms, more use of healthcare 
services, and higher GI symptom related costs than those identified by just Manning 
criteria. This finding can partly be explained by the lesser requirement of pain in Manning 
criteria. Of the six Manning symptoms, only three are related to pain (looser stools at 
onset of pain, more frequent bowel movements at onset of pain, and pain eased after 
bowel movement). Abdominal pain disturbs daily activities and it predicts the use of the 
healthcare system which incurs economic expenses. According to the coding system in the 
Rome II Integrative Questionnaire, the required frequency of abdominal pain or 
discomfort to fulfil the criteria is “often”, which means more frequently than one day out 
of four. In the original Rome II criteria, the required frequency of abdominal pain is at 
least once a week for a period of 12 weeks during the previous 12 months. The reason for 
the higher requirement of pain in the Questionnaire is possibly to concentrate a more 
homogenous IBS group for research purposes and clinical trials, although this has not 
been commented on by the authors of the Rome II book
19
. In the widely used Rome II 
Modular Questionnaire, the required frequency of abdominal pain or discomfort is also 






weeks (at least one day in each week)”
19
. This interpretation of “often” would generate an 
IBS prevalence of 9.3% in our population sample. In the Rome III Questionnaire, the 
required frequency of abdominal pain or discomfort is at least two to three days a month. 
In pathophysiology research and clinical trials, however, a frequency of at least two days a 
week during screening evaluation is recommended for subject eligibility
276
. 
Rome II criteria have been criticised as too restrictive for research and practice
75
. In 
addition, poor agreement between IBS diagnosis by general practitioners and Rome II 
criteria has been shown
277
. A clinician’s diagnosis is usually based on a global conception 
of a patient’s symptoms and clinical signs rather than on a standardised questionnaire. 
According to the Rome II definition, a high proportion of patients with IBS-type 
symptoms, but only occasional abdominal pain or discomfort, would fit into categories 
with no requirement of pain, such as functional constipation, functional diarrhoea, or 
unspecified functional bowel disorder
278
.  
Depression and anxiety 
The presence of depressive symptoms and anxiety is higher in the IBS population than 
among controls regardless of applied criteria. Half of the respondents fulfilling the Rome 
II criteria reported depressive symptoms or anxiety (II).  Of those with at least one 
physician visit for GI symptoms, 43% had depressive symptoms, but these symptoms 
were not independent predictors of GI visits. Our results show that psychiatric 
comorbidity in IBS is not limited to healthcare seekers, but also exists among 
non-consulters (II). In two studies from Scandinavia, high frequencies of psychiatric 




Depressive symptoms are prevalent in the general population regardless of IBS. In our 
study, 17% of participants reported at least mild depressive symptoms. Prevalence of 
clinical depression in Finnish population studies have ranged between 5% to 9%
138,279
. 
Differences between prevalence estimates are probably due to different study 
methodology as these studies used the University of Michigan Composite International 
Diagnostic Interview (UM-CICI). Moreover, we used a cut-off level of 4/5 in R-BDI-SF, 
originally suggested for general population screening
267
, while a higher cut-off point of 
7/8 has also been recommended to increase the specificity of R-BDI-SF for detection of 
depression among adolescents
280
. Thus, our results also include mild depressive 
symptoms.  
Depressive symptoms were associated with a high rate of GI symptoms, and IBS was 
more than three times as common among subject with depressiveness. In addition, 
presence of depressive symptoms was associated with increased use of healthcare services 
and work absenteeism for GI reasons (III).  
In former studies, high co-occurrence of psychiatric and GI symptoms has been 
observed among healthcare users with IBS
281-283
. Our results suggest that overlap of 
depression and GI symptoms is also considerable in general population. Possible reasons 








, or a lower threshold of interpreting signals from GI tract 
as disturbing. No conclusions on causality, however, can be made from the present 
cross-sectional study.  
Comorbidity 
In the general population, several somatic and psychiatric symptoms are overrepresented 
among subjects fulfilling Rome II criteria of IBS.  
Almost half of the subjects meeting Rome II IBS criteria reported symptoms consistent 
with dyspepsia, compared with only 6% of those without IBS. Earlier reports show a 
similar overlap with IBS and functional dyspepsia
9,152,286
. This high co-occurrence is 
suggestive of a common pathophysiological basis, or only one disorder with different 
symptom manifestations.  
Of those meeting the Rome II IBS criteria, 69% reported somatic symptoms, such as 
headache, back pain, allergy, or asthma compared to 35% among controls. In previous 
studies, chronic headache are reported by 23 to 35% and back pain by 28 to 81% of 
subjects with IBS
287,288
, in line with our findings.  
Some studies report an increased rate of asthma or bronchial hyper-responsiveness 
among subjects with IBS
92,161,289
. In the present study, diagnosis of asthma was reported 
2.4 times more frequently by subjects with IBS than by controls (II). IBS has also been 
associated with a positive methacholine test
290
, although not confirmed
291,292
. Several 
theories of a common pathogenesis exist to explain the co-occurrence of asthma and IBS. 
A disorder affecting both bronchial and GI tract involved with smooth muscle, 
neuromuscular, or inflammatory system is possible, but needs further study. No significant 
difference was detected, however, in the frequency of food allergy in our study (II).   
Healthcare seeking 
IBS is associated with an elevated rate of physician visits for both GI and non-GI reasons. 
In our study, 48 to 49% of subjects meeting either Rome criteria had consulted a physician 
for abdominal symptoms during the previous year (I), in line with consultation rates in 
former studies
229,231
. In a previous study from Finland, 75 to 81% of the population had 
made at least one physician visit for any reason during the previous year
293
. In our study, 
80% of subjects in the control group had at least one non-GI visit, compared with an even 
higher share of 86 to 89% of those meeting any IBS criteria. The higher share of non-GI 






Predictors of GI consultations 
The main predictors for GI visits were disturbing abdominal symptoms, severe abdominal 
pain, dyspeptic symptoms, lactose intolerance, and IBS (II). Of the non-GI symptoms, 
only insomnia and headache, but not depression nor anxiety, were predictive for GI visits. 
This is in line with an Australian study by Talley et al.
229
, where pain severity, but not 
psychological comorbidity, was an independent predictor of GI visits. 
In previous literature, the role of psychiatric symptoms as predictors of healthcare use 
is inconclusive. Anxiety, depression, somatisation, and lowered QoL are associated with 
increased healthcare use
108,231,234,294
. In other population based studies, however, 
psychological factors did not explain healthcare seeking for abdominal reasons
229,231
.  
In our study, co-occurrence of IBS and other somatic or psychiatric symptoms did not 
elevate the likelihood of consulting for GI reasons. In fact, the combination of lactose 
intolerance and IBS lowered the probability of consultation, perhaps because of such 
individuals having already consulted earlier and attributing their GI symptoms as lactose 
ingestion not needing physician care. Overall, our results indicate that the predictors for 
consulting are not different for those with IBS compared to controls.  
Predictors of non-GI consultations 
Presence of IBS had no impact on consultation rates for non-GI visits. Young age and 
presence of a chronic medical condition were the strongest predictors for them. The need 
for physician consultations and statements for applying for a job, studying, or driver’s 
license may explain young age as a predictor for non-GI visits. Of the GI disorders and 
symptoms listed (dyspepsia, IBS, diarrhoea, constipation, lactose intolerance, history of 
abdominal surgery, celiac disease, and abdominal pain), only the presence of dyspeptic 
symptoms predicted non-GI visits. One reason for dyspeptic symptoms predicting non-GI 
visits may be the patient’s concern of possible serious disease, such as heart disease 
causing the upper abdominal symptoms
295
.  It is also possible that dyspepsia is associated 
with other non-GI comorbidities, but not covered by our questionnaire, influencing 
healthcare use.    
Societal costs 
Due to high prevalence rates and frequent healthcare use, IBS generates a considerable 
economic burden. Our study indicates that 2 to 5% of the working age population annually 
consults a physician for their IBS symptoms.  Those meeting Rome II criteria incur 1.7 
times higher GI related costs per subject as those meeting the more lax Manning 2 criteria 
(497€ vs. 295€) (IV). Nationwide, however, expenditures are almost twice as high for 
Manning 2 as Rome II criteria (154M€ vs. 82M€), because of the considerable difference 






criteria. Overall, we obtained more modest individual GI costs compared to previous 
studies assessing IBS costs in Europe
245,246
.    
No gender difference was detected in GI related costs per subject, although some 
studies have found up to 3.3 times higher consultation rates for females
105,116,233,296
. In the 
study by Drossman et al.
105
, 44% of females and 35% of males with a functional GI 
disorder by Rome I criteria had visited a physician for GI symptoms during the previous 
year. In our study, 53% of females and 44% of males fulfilling Rome I criteria for IBS had 
made at least one physician visit for GI reasons (p = 0.205). In the database study by Shih 
et al.
233
, differences in healthcare use between genders were partly explained by gender 
differences in the population prevalence of IBS. Other studies from the UK, US, and 
Australia have, however, found no difference in consultation behaviour between 
genders
77,229,231
. Likewise, two previous studies reported no gender difference in IBS 
costs
243,246
. It is possible that cultural differences in healthcare use between genders in 
different countries exist, but this issue needs further study.  
The principal cost component was the share of physician visits, covering 40 to 42% of 
the total annual costs. The average annual number of visits for GI symptoms ranged 
between 1.0 (Manning 2 criteria) and 1.8 (Rome II criteria). Higher number of annual 







, and the US (3.7)
249
. In the US Householder study
105
, the number of GI visits 
was 1.64, closer to our findings.  
Of the total GI expenditures, indirect costs covered 32 to 34% (IV). In previous 
studies, a wide range of 16 to 82% has been reported to represent the share of indirect 
costs in IBS. In a review, three out of five studies reported a proportion of more than 70% 
of the total costs. The main factor of indirect costs is sick leave cost. In our study, the 
mean number of sick leave days was 0.9 for those meeting Manning 2 criteria, 
considerably less than the 2.2 days in the French study
246
.   Previous studies from the UK 
and US have reported even higher numbers of IBS-related sick leave days, ranging 
between 8.5 and 21.6 per year
248
. In our study, almost one third of subjects meeting Rome 
II criteria reported impaired performance at work weekly or more often indicating that 
they tend to go to work despite of GI symptoms rather than take sick leave. This may 
partly explain the lower than previously detected missed work days in our present study.  
The duration of GI symptoms had no effect on total GI costs, or costs of endoscopies. 
IBS is a chronic disorder typically with fluctuating severity of symptoms. Repeating 
diagnostic procedures is not suggested, as the diagnosis is not likely to change over 
time
81,297
. That the costs of endoscopies were not lower for those with several years of IBS 
symptoms may indicate that contrary to guideline recommendations, diagnostic 
procedures are repeated, or the first procedure is performed late in the course of GI 
symptoms. On the other hand, situations not covered by a cross sectional setting, such as a 
change in symptoms or appearance of new alarm symptoms, may also explain the finding.    
In our present study, subjects meeting Manning 2 or Rome II criteria made 1.3 to 1.4 
times more non-GI physician visits than controls. The direct costs of GI symptoms and 
non-GI visits amounted to 98M€ by Rome II and 230M€ by Manning 2 criteria, equivalent 
to a substantial share of 2 to 5% of the 4 562M€ expenditures on outpatient healthcare and 






related to suffering from pain and reduced QoL, which cannot be properly measured in 
monetary terms. An integral approach to IBS by physicians, to also consider comorbid 
conditions, may produce a more favourable course in IBS patients and even reduce 








SUMMARY AND CONCLUSIONS 
 
Our study investigated the prevalence of IBS according to varying diagnostic criteria, 
somatic and psychiatric comorbity, healthcare resource use, and societal costs.  
The prevalence of IBS shows a substantial variation depending on the criteria applied. 
Manning criteria with at least two of the six Manning symptoms represent the broadest 
interpretation of IBS giving a three-fold prevalence figure compared to Rome II, the 
strictest criteria. Subjects fulfilling Rome II criteria form a subgroup of those fulfilling 
Manning 2 criteria with more severe GI symptoms, more frequent health care resource use 
and higher societal costs per subject.  
IBS, by Rome II criteria, is associated with a high level of somatic and psychiatric 
comorbidity among both healthcare consulters and non-consulters. Healthcare seeking for 
GI symptoms is predicted by symptom severity rather than psychiatric comorbidity. 
Presence of dyspeptic symptoms also predicts healthcare seeking for non-GI symptoms.  
Depressive symptoms are prevalent in the general population and are associated with 
an increased level of GI symptoms, physician visits, and work absenteeism for GI 
symptoms. 
The economic burden of IBS is considerable. Direct costs of GI symptoms and non-GI 
consultations correspond to a share of up to 5% of the outpatient healthcare and medicine 
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8. Onko lääkäri todennut Teillä
keliakia-sairauden?


























2. Vastaajan ikä: vuotta
Nainen Mies
1. Vastaajan sukupuoli
Ei Kyllä En osaa sanoa
7. Onko lääkäri todennut Teillä maitosokerin
imeytymishäiriön eli laktoosi-intoleranssin?
9. Onko lääkäri todennut Teillä lapsuudessa
(alle 15 -vuotiaana) seuraavia sairauksia:
a) Ruoka-aineallergia?
Ei Kyllä En osaa sanoa
b) Atooppinen ihottuma?
Ei Kyllä En osaa sanoa
c) Astma?
Ei Kyllä En osaa sanoa
d) Allerginen nuha?
Ei Kyllä En osaa sanoa
Ei Kyllä En osaa sanoa
10. Esiintyikö Teillä lapsuudessa (alle 15
-vuotiaana) muita enemmän vatsakipuja?
Ei Kyllä, milloin? Vuonna
12. Onko Teille tehty sappileikkaus?
11. Onko umpilisäkkeenne leikattu?
Ei Kyllä, milloin? Vuonna
b) Paksusuolen tähystys?
Ei Kyllä, viimeksi vuonna
a) Mahalaukun tähystys?
Ei Kyllä, viimeksi vuonna




13. Onko Teille tehty jokin muu suoliston tai
vatsan alueen leikkaus?
15. Onko Teillä jokin pitkäaikaissairaus?
Ei Kyllä, mikä?
16. Onko Teillä säännöllinen lääkitys?




Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Lähes aina
23. Muuttuiko ulosteenne koostumus tavallista löysemmäksi edellä mainitun vatsakivun tai -vaivan
alkaessa?
2
Mikäli vastasitte "harvoin tai ei ollenkaan", voitte siirtyä suoraan kysymykseen 30, muussa tapauksessa
vastatkaa vielä seuraaviin kysymyksiin:
18. Kuinka usein viimeksi kuluneen vuoden aikana vatsakipu tai vatsavaiva häiritsi päivittäisiä
askareitanne?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä päivänä kymmenestä)
Usein (useammin kuin yhtenä päivänä neljästä)
Hyvin usein (vähintään joka toinen päivä)
Jatkuvasti (päivittäin)
Lievää (voi helposti jäädä huomaamatta, ellei sitä ajattele)
Kohtalaista (oire on olemassa, mutta ei häiritse päivän toimintoja)
Voimakasta (oire häiritsee päivän toimintoja)
Erittäin voimakasta (oire häiritsee merkittävästi päivän toimintoja)
19. Kuinka voimakasta edellä mainittu vatsaoire on yleensä ollut viimeisen vuoden aikana?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Lähes aina
20. Helpottuiko edellä mainittu vatsakipu tai vatsavaiva ulostamisen jälkeen?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Lähes aina
21. Muuttuiko suolentoimintanne (ulostamistiheys) tavallista tiheämmäksi edellä mainitun vatsakivun tai
-vaivan alkaessa?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Lähes aina
22. Muuttuiko suolentoimintanne tavallista harvemmaksi edellä mainitun vatsakivun tai -vaivan
alkaessa?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Lähes aina
24. Muuttuiko ulosteenne koostumus tavallista kovemmaksi edellä mainitun vatsakivun tai -vaivan
alkaessa?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä päivänä kymmenestä)
Usein (useammin kuin yhtenä päivänä neljästä)
Hyvin usein (vähintään joka toinen päivä)
Jatkuvasti (päivittäin)
17. Kuinka usein Teillä on ollut vatsakipua tai vatsavaivaa (vatsan seudun epämiellyttävää tunnetta)
viimeksi kuluneen vuoden aikana?
0188616505
3
25. Mitkä tekijät pahentavat vatsaoireitanne?
a) Ruokailu?
Ei pahenna Pahentaa joskus oireita Pahentaa usein oireita
Pahentaa aina oireita En osaa sanoa
b) Maito tai maitotuotteet?
Eivät pahenna Pahentavat joskus oireita Pahentavat usein oireita
Pahentavat aina oireita En osaa sanoa
Mitä oireita saatte maitotuotteista?
Mitkä maitotuotteet aiheuttavat oireita?
c) Viljatuotteet?
Eivät pahenna Pahentavat joskus oireita Pahentavat usein oireita
Pahentavat aina oireita En osaa sanoa
Mitä oireita saatte viljatuotteista?
Mitkä viljatuotteet aiheuttavat oireita?
d) Jotkin muut tekijät tai ruoka-aineet? Mitkä?
Jos vastasitte "harvoin tai ei ollenkaan", voitte siirtyä kysymykseen 30, muussa tapauksessa vastatkaa
vielä seuraavaan:
Minkälaisia oireita ne aiheuttavat?
26. Onko Teillä ollut viimeksi kuluneen vuoden aikana usein vatsakipua tai vatsavaivaa (vatsan seudun
epämiellyttävää tunnetta)? Usein tarkoittaa tässä yhteydessä oireen esiintymistä vähintään kerran
viikossa ainakin 12 eri viikkona viimeisen vuoden aikana.
Ei Kyllä
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä päivänä kymmenestä)
Usein (useammin kuin yhtenä päivänä neljästä)
Hyvin usein (vähintään joka toinen päivä)
Jatkuvasti tai lähes jatkuvasti
27. Kuinka usein viimeksi kuluneen vuoden aikana Teillä on ollut ylävatsalla (navan yläpuolella) tuntuvaa
kipua? Närästystä eli rintalastan takana tuntuvaa polttelua ei lasketa mukaan.
28. Kuinka usein viimeisen vuoden aikana Teillä on ollut ylävatsalla tuntuvaa muuta epämukavuuden
tunnetta, esim. pahoinvointia, ylävatsan turvotusta tai ruokailun yhteydessä varhaista vatsan
täyttymisen tunnetta?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä päivänä kymmenestä)
Usein (useammin kuin yhtenä päivänä neljästä)
Hyvin usein (vähintään joka toinen päivä)
Jatkuvasti tai lähes jatkuvasti
29. Kuinka voimakasta edellä mainittu  ylävatsaoire on yleensä ollut viimeisen vuoden aikana?
Lievää (voi helposti jäädä huomaamatta, ellei sitä ajattele)
Kohtalaista (oire on olemassa, mutta ei häiritse päivän toimintoja)
Voimakasta (oire häiritsee päivän toimintoja)
Erittäin voimakasta (oire häiritsee merkittävästi päivän toimintoja)
1942616504
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Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Aina tai lähes aina
37. Kuinka usein viimeksi kuluneen vuoden aikana olette huomannut limaa ulosteissanne?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä päivänä kymmenestä)
Usein (useammin kuin yhtenä päivänä neljästä)
Hyvin usein (vähintään joka toinen päivä)
Jatkuvasti tai lähes jatkuvasti
30. Kuinka usein viimeksi kuluneen vuoden aikana Teillä oli enemmän kuin kolme ulostuskertaa
päivässä?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä viikkona kymmenestä)
Usein (useammin kuin yhtenä viikkona neljästä)
Hyvin usein (vähintään joka toinen viikko)
Jatkuvasti tai lähes jatkuvasti
31. Kuinka usein viimeksi kuluneen vuoden aikana Teillä oli vähemmän kuin kolme ulostuskertaa
viikossa?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Jatkuvasti tai lähes jatkuvasti
32. Kuinka usein viimeksi kuluneen vuoden aikana ulosteenne oli kovaa, kokkaremaista tai
papanamaista?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Jatkuvasti tai lähes jatkuvasti
33. Kuinka usein viimeksi kuluneen vuoden aikana ulosteenne oli löysää tai vetistä?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Jatkuvasti tai lähes jatkuvasti
34. Kuinka usein viimeksi kuluneen vuoden aikana Teille jäi ulostamistapahtuman jälkeen tunne, että
peräsuolenne ei tyhjentynyt kunnolla?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Aina tai lähes aina
35. Kuinka usein viimeksi kuluneen vuoden aikana Teidän oli  ponnisteltava runsaasti saadaksenne
peräsuolenne tyhjentymään?
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä kertana kymmenestä)
Usein (useammin kuin yhtenä kertana neljästä)
Hyvin usein (vähintään joka toinen kerta)
Aina tai lähes aina
36. Kuinka usein viimeksi kuluneen vuoden aikana Teillä on ollut pakottava ulostamisen tarve, jonka
vuoksi Teidän on täytynyt kiirehtiä  wc:hen?
6842616508
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Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä päivänä kymmenestä)
Usein (useammin kuin yhtenä päivänä neljästä)
Hyvin usein (vähintään joka toinen päivä)
Jatkuvasti tai lähes jatkuvasti
38. Kuinka usein viimeksi kuluneen vuoden aikana Teillä on ollut vatsan turvotusta?











40. Kuinka monta kertaa viimeisen vuoden aikana olette käynyt lääkärin vastaanotolla muiden syiden
kuin vatsavaivojen vuoksi?
En lainkaan
Harvemmin kuin kerran kuukaudessa
Keskimäärin 1-3 kertaa kuukaudessa
Keskimäärin 1-3 kertaa viikossa
Päivittäin tai lähes päivittäin
42. Kuinka usein olette viimeisen vuoden aikana käyttänyt vatsaoireiden vuoksi lääkärin määräämiä
lääkkeitä?
44. Kuinka usein Teillä esiintyy seuraavia oireita?
a) Päänsärkyä?
Harvemmin kuin kerran kuukaudessa
1-3 kertaa kuukaudessa
1-3 kertaa viikossa
Useammin kuin 3:sti viikossa
Harvemmin kuin kerran kuukaudessa
1-3 kertaa kuukaudessa
1-3 kertaa viikossa
Useammin kuin 3:sti viikossa
b) Selkäkipua?






En ole ollut työssä viimeisen vuoden aikana
En lainkaan
Harvemmin kuin kerran kuukaudessa
Keskimäärin 1-3 kertaa kuukaudessa
Keskimäärin 1-3 kertaa viikossa
Päivittäin tai lähes päivittäin
43. Kuinka usein olette viimeisen vuoden aikana käyttänyt vatsaoireiden vuoksi reseptivapaita
käsikauppalääkkeitä?
1161616507
46. Miten suhtaudutte tulevaisuuteen?
Suhtaudun tulevaisuuteeni toiveikkaasti
En suhtaudu tulevaisuuteeni toivottomasti
Tulevaisuus tuntuu minusta melko masentavalta
Minusta tuntuu, ettei minulla ole tulevaisuudelta mitään odotettavaa
Tulevaisuus tuntuu minusta toivottomalta, enkä jaksa uskoa, että asiat muuttuisivat parempaan päin
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Lopuksi esitämme eräitä kysymyksiä, jotka käsittelevät mielialan erilaisia piirteitä.  Vastatkaa kuhunkin
kysymykseen merkitsemällä rasti siihen kysymyksen jäljessä olevaan ruutuun, joka parhaiten kuvaa Teidän
tilannettanne tällä hetkellä. Valitkaa kustakin kysymyksestä vain yksi vaihtoehto älkääkä jättäkö yhtään
kysymystä väliin.
45. Minkälainen Teidän mielialanne on?
Mielialani on melko valoisa ja hyvä
En ole alakuloinen tai surullinen
Tunnen itseni alakuloiseksi tai surulliseksi
Olen alakuloinen jatkuvasti enkä pääse siitä
Olen niin masentunut ja alavireinen, etten kestä enää
47. Miten katsotte elämänne sujuneen?
Olen elämässäni onnistunut huomattavan usein
En tunne epäonnistuneeni elämässäni
Minusta tuntuu, että olen epäonnistunut pyrkimyksissäni tavallista useammin
Elämäni on tähän saakka ollut vain sarja epäonnistumisia
Tunnen epäonnistuneeni täydellisesti ihmisenä
48. Miten tyytyväiseksi tai tyytymättömäksi tunnette itsenne?
Olen varsin tyytyväinen elämääni
En ole erityisen tyytymätön
En nauti asioista samalla tavalla kuin ennen
Minusta tuntuu, etten saa tyydytystä juuri mistään
Olen täysin tyytymätön kaikkeen
49. Minkälaisena pidätte itseänne?
Tunnen itseni melko hyväksi
En tunne itseäni huonoksi ja arvottomaksi
Tunnen itseni huonoksi ja arvottomaksi melko usein
Nykyään tunnen itseni arvottomaksi melkein aina
Olen kerta kaikkiaan arvoton ja huono
50. Onko Teillä pettymyksen tunteita?
Olen tyytyväinen itseeni ja suorituksiini
En ole pettynyt itseni suhteen
Olen pettynyt itseni suhteen
Minua inhottaa oma itseni
Vihaan itseäni
51. Onko Teillä itsenne vahingoittamiseen liittyviä ajatuksia?
Minulla ei ole koskaan ollut itsemurha-ajatuksia
En ajattele enkä halua vahingoittaa itseäni
Minusta tuntuu, että olisi parempi, jos olisin kuollut
Minulla on tarkat suunnitelmat itsemurhasta
Tekisin itsemurhan, jos siihen olisi mahdollisuus
52. Miten suhtaudutte vieraitten ihmisten tapaamiseen?
Pidän ihmisten tapaamisesta ja juttelemisesta
En ole menettänyt kiinnostustani muihin ihmisiin
Toiset ihmiset eivät enää kiinnosta minua niin paljon kuin ennen
Olen melkein kokonaan menettänyt mielenkiintoni ja tunteeni toisia ihmisiä kohtaan
Olen menettänyt mielenkiintoni muihin ihmisiin, enkä välitä heistä lainkaan
3833616505
58. Oletteko ahdistunut tai jännittynyt?
Pidän itseäni melko hyvähermoisena enkä ahdistu kovinkaan helposti
En tunne itseäni ahdistuneeksi tai "huonohermoiseksi"
Ahdistun ja jännityn melko helposti
Tulen erityisen helposti tuskaiseksi, ahdistuneeksi tai jännittyneeksi
Tunnen itseni jatkuvasti ahdistuneeksi ja tuskaiseksi kuin hermoni olisivat "loppuun kuluneet"
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53. Miten koette päätösten tekemisen?
Erilaisten päätösten tekeminen on minulle helppoa
Pystyn tekemään päätöksiä samoin kuin ennenkin
Varmuuteni on vähentynyt ja yritän lykätä päätösten tekoa
Minulla on suuria vaikeuksia päätösten teossa
En pysty enää lainkaan tekemään ratkaisuja ja päätöksiä
54. Minkälaisena pidätte olemustanne ja ulkonäköänne?
Olen melko tyytyväinen ulkonäkööni ja olemukseeni
Ulkonäössäni ei ole minua haittaavia piirteitä
Olen huolissani siitä, että näytän epämiellyttävältä
Minusta tuntuu, että näytän rumalta
Olen varma, että näytän rumalta ja vastenmieliseltä
55. Minkälaista Teidän nukkumisenne on?
Minulla ei ole nukkumisessa minkäänlaisia vaikeuksia
Nukun yhtä hyvin kuin ennenkin
Herätessäni aamuisin olen paljon väsyneempi kuin ennen
Minua haittaa unettomuus
Kärsin unettomuudesta, nukahtamisvaikeuksista tai liian aikaisin kesken unien heräämisistä
56. Tunnetteko väsymystä tai uupumusta?
Väsyminen on minulle lähes täysin vierasta
En väsy helpommin kuin tavallisestikaan
Väsyn nopeammin kuin ennen
Vähäinenkin työ väsyttää ja uuvuttaa minua
Olen liian väsynyt tehdäkseni mitään
57. Minkälainen ruokahalunne on?
Ruokahalussani ei ole mitään hankaluuksia
Ruokahaluni on ennallaan
Ruokahaluni on huonompi kuin ennen
Ruokahaluni on nyt paljon huonompi kuin ennen
Minulla ei ole enää lainkaan ruokahalua








Jokin muu oire, mikä?
Vatsakipu ..................................................................
3. Luettelemme seuraavaksi 5 erilaista vatsaoiretta. Nimetkää näistä pahin oireenne laittamalla numero
1 oireen vieressä olevaan ruutuun, toiseksi pahin numerolla 2 jne. Mikäli kärsitte jostakin muusta
vatsaoireesta, kirjoittakaa se vapaaseen tilaan ja merkitkää sen viereen sopivaksi katsomanne numero
oireen hankaluuden mukaan.
1. Kuinka kauan Teillä on ollut vatsavaivoja?
Alle vuoden ajan 1-3 vuotta 3-10 vuotta Yli 10 vuotta
Pysyneet ennallaan Lisääntyneet Vähentyneet
2. Ovatko vatsaoireenne viimeisen 3 kuukauden aikana pysyneet ennallaan, lisääntyneet vai
vähentyneet?
Mikäli vastasitte "harvoin tai ei ollenkaan", voitte siirtyä seuraavalle sivulle kysymykseen 7, muussa






6. Mikäli valitsitte edelliseen kysymykseen useamman kuin yhden
alueen, pyydämme Teitä vielä arvioimaan, millä näistä alueista
oleva kipu tai vaiva häiritsee Teitä eniten? Valitkaa nyt vain yksi





5. Millä alueella vatsakipunne tai -vaivanne tuntuu? Valitkaa oheisen kaavakuvan mukaisesti
tilannettanne parhaiten kuvaava alue A,B,C tai D. Voitte valita myös useamman kuin yhden kirjaimen,
mikäli oireenne tuntuu laajemmalla alueella. Merkitkää vastauksenne rastilla (X) asianomaisten kirjainten
kohdalla oleviin ruutuihin.
Harvoin tai ei ollenkaan
Toisinaan (useammin kuin yhtenä päivänä kymmenestä)
Usein (useammin kuin yhtenä päivänä neljästä)
Hyvin usein (vähintään joka toinen päivä)
Jatkuvasti (päivittäin)
4. Kuinka usein Teillä on ollut vatsakipua tai vatsavaivaa (vatsan seudun epämiellyttävää tunnetta)




8. Oletteko käynyt lääkärissä vatsavaivojenne takia viimeisen vuoden aikana?





Ei kertaakaan Kerran 2 kertaa 3 kertaa Yli 3 kertaa
Ei kertaakaan Kerran 2 kertaa 3 kertaa Yli 3 kertaa
Ei kertaakaan Kerran 2 kertaa 3 kertaa Yli 3 kertaa
Ei kertaakaan Kerran 2 kertaa 3 kertaa Yli 3 kertaa
Mikäli vastasitte "En", voitte siirtyä seuraavalle sivulle kysymykseen 14, mikäli  vastasitte
"Kyllä", jatkakaa seuraavasta kysymyksestä:
En kertaakaan Kerran 2 kertaa 3 kertaa 4-6 kertaa yli 6 kertaa
9. Kuinka monta kertaa viimeisen vuoden aikana olette käynyt vatsavaivojenne takia
terveyskeskuslääkärin vastaanotolla?
10. Kuinka monta kertaa viimeisen vuoden aikana olette käynyt vatsavaivojenne takia
työterveyslääkärin vastaanotolla?
En kertaakaan Kerran 2 kertaa 3 kertaa 4-6 kertaa yli 6 kertaa
En kertaakaan Kerran 2 kertaa 3 kertaa 4-6 kertaa yli 6 kertaa
13. Kuinka monta kertaa viimeisen vuoden aikana olette käynyt vatsavaivojenne takia yksityislääkärin
vastaanotolla? (Tässä ei tarkoiteta käyntejä yksityisellä lääkäriasemalla työterveyslääkärin luona)
En kertaakaan Kerran 2 kertaa 3 kertaa 4-6 kertaa yli 6 kertaa
12. Kuinka monta kertaa viimeisen vuoden aikana olette käynyt vatsavaivojenne takia sairaalan
päivystyspoliklinikalla (ensiapupoliklinikalla)?
En kertaakaan Kerran 2 kertaa 3 kertaa 4-6 kertaa yli 6 kertaa
11. Kuinka monta kertaa viimeisen vuoden aikana olette käynyt vatsavaivojenne takia sairaalan
ajanvarauspoliklinikalla (sisätautien tai kirurgian poliklinikalla)?
0226395894
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14. Kuinka usein viimeksi kuluneen 3 kuukauden aikana vatsaoireenne on haitannut Teidän
työntekoanne töissä ollessanne?
Ei ollenkaan
Harvemmin kuin 2 päivänä kuukaudessa
2-3 päivänä kuukaudessa
1-2 päivänä viikossa
3 päivänä viikossa tai useammin
En ole ollut töissä viimeisten 3 kuukauden aikana
En kertaakaan
Harvemmin kuin 2 kertaa kuukaudessa
Keskimäärin 2-3 kertaa kuukaudessa
Keskimäärin 1-2 kertaa viikossa
Keskimäärin 3-5 kertaa viikossa
Päivittäin tai lähes päivittäin
18. Kuinka usein viimeksi kuluneen 3 kuukauden aikana olette käyttänyt vatsavaivojenne takia
reseptivapaata kipulääkettä, kuten  Aspirin, Disperin, Primaspan, Burana, Ibusal, Ketomex, Ketorin,
Orudis, Panadol, Para-tabs?
En kertaakaan
Harvemmin kuin 2 kertaa kuukaudessa
Keskimäärin 2-3 kertaa kuukaudessa
Keskimäärin 1-2 kertaa viikossa
Keskimäärin 3-5 kertaa viikossa
Päivittäin tai lähes päivittäin
15. Kuinka usein viimeksi kuluneen 3 kuukauden aikana olette käyttänyt vatsavaivojenne takia jotain
seuraavista reseptivapaista "närästyslääkkeistä": Balancid, Gaviscon, Link, Magnesiamaito, Novaluzid,
PeeHoo, PH maxi, Rennie, Alsucral, Antepsin?
En kertaakaan
Harvemmin kuin 2 kertaa kuukaudessa
Keskimäärin 2-3 kertaa kuukaudessa
Keskimäärin 1-2 kertaa viikossa
Keskimäärin 3-5 kertaa viikossa
Päivittäin tai lähes päivittäin
16. Kuinka usein viimeksi kuluneen 3 kuukauden aikana olette käyttänyt vatsavaivojenne takia jotain
seuraavista mahan suolahapon eritystä vähentävistä lääkkeistä: Esofex, Ranicur, Ranil, Ranimex,
Ranitidine, Ranitidin, Ranixal, Zantac, Pepcid, Pepcidin, Nizax?
En kertaakaan
Harvemmin kuin 2 kertaa kuukaudessa
Keskimäärin 2-3 kertaa kuukaudessa
Keskimäärin 1-2 kertaa viikossa
Keskimäärin 3-5 kertaa viikossa
Päivittäin tai lähes päivittäin
17. Kuinka usein viimeksi kuluneen 3 kuukauden aikana olette käyttänyt vatsavaivojenne takia jotain
seuraavista mahan suolahapon eritystä vähentävistä lääkkeistä: Lanzo, Losec, Nexium, Pariet, Somac?
En kertaakaan
Harvemmin kuin 2 kertaa kuukaudessa
Keskimäärin 2-3 kertaa kuukaudessa
Keskimäärin 1-2 kertaa viikossa
Keskimäärin 3-5 kertaa viikossa
Päivittäin tai lähes päivittäin
19. Kuinka usein viimeksi kuluneen 3 kuukauden aikana olette käyttänyt vatsavaivojenne takia jotain




Harvemmin kuin 2 kertaa kuukaudessa
Keskimäärin 2-3 kertaa kuukaudessa
Keskimäärin 1-2 kertaa viikossa
Keskimäärin 3-5 kertaa viikossa
Päivittäin tai lähes päivittäin
20. Kuinka usein viimeksi kuluneen 3 kuukauden aikana olette käyttänyt vatsavaivojenne takia jotain
seuraavista ummetuksen hoitoon tarkoitetuista lääkkeistä: Pursennid, Sennapur, Metalax, Toilax,
Laxoberon, Duphalac, Levolac, Loraga, Movicol, Klyx, Microlax?
21. Kuinka usein viimeksi kuluneen 3 kuukauden aikana olette käyttänyt vatsavaivojenne takia jotain
seuraavista kuituvalmisteista: Agiocur, Agiolax, Laxamucil, Vi-Siblin?
En kertaakaan
Harvemmin kuin 2 kertaa kuukaudessa
Keskimäärin 2-3 kertaa kuukaudessa
Keskimäärin 1-2 kertaa viikossa
Keskimäärin 3-5 kertaa viikossa
Päivittäin tai lähes päivittäin
En kertaakaan
Harvemmin kuin 2 kertaa kuukaudessa
Keskimäärin 2-3 kertaa kuukaudessa
Keskimäärin 1-2 kertaa viikossa
Keskimäärin 3-5 kertaa viikossa
Päivittäin tai lähes päivittäin
22. Kuinka usein viimeksi kuluneen 3 kuukauden aikana olette käyttänyt vatsavaivojenne takia jotain
seuraavista suolistoperäisiä kiputiloja lievittävistä reseptilääkkeistä: Buscopan, Egazil Duretter,
Gastrodyn comp, Librax, Spasmo-Oxepam, Litalgin?
23. Kuinka usein viimeksi kuluneen 3 kuukauden aikana olette käyttänyt vatsavaivojenne takia jotain
seuraavista suoliston toimintaan vaikuttavista reseptilääkkeistä: Metopram, Primperan, Prepulsid,
Doryl, Mestinon, Ubretid?
En kertaakaan
Harvemmin kuin 2 kertaa kuukaudessa
Keskimäärin 2-3 kertaa kuukaudessa
Keskimäärin 1-2 kertaa viikossa
Keskimäärin 3-5 kertaa viikossa
Päivittäin tai lähes päivittäin
24. Onko Teillä ollut viimeksi kuluneen 3 kuukauden aikana ollut käytössä jokin seuraavista masennus- eli
depressiolääkkeistä:
a) Triptyl, Klotriptyl, Saroten, Pertriptyl, Suprium, Doxal, Tolvon?
Kyllä Ei
b) Seronil, Seromex, Fontex, Fevarin, Seroxat, Cipramil?
Kyllä Ei
25. Oletteko käyttänyt viimeksi kuluneen 3 kuukauden aikana vatsavaivojenne hoitoon joitakin muita
kuin edellisissä kysymyksissä mainittuja lääkkeitä?
En Kyllä, mitä lääkkeitä? (Kirjoittakaa lääkkeiden kauppanimet viivalle)
c) Jokin muu masennuslääke? Mikä? (Kirjoittakaa lääkkeen kauppanimi viivalle)
9600395899
31. Huomattavia ponnistuksia vaativat toiminnat (esimerkiksi
 juokseminen, raskaiden tavaroiden nostelu, rasittava urheilu)............................................................
Seuraavassa luetellaan erilaisia päivittäisiä toimintoja. Rajoittaako terveydentilanne nykyisin
suoriutumistanne seuraavista päivittäisistä toiminnoista? Jos rajoittaa, kuinka paljon? (Merkitkää joka
riville yksi rasti sopivaan ruutuun)
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Seuraavat kysymykset liittyvät yleiseen terveydentilaanne. Rastittakaa yksi vaihtoehto, joka parhaiten
kuvaa tilannettanne.
27. Onko lähisuvussanne (vanhemmillanne, sisaruksillanne tai lapsillanne) seuraavia sairauksia:
Paksu- tai peräsuolen syöpä? Ei Kyllä En tiedä
Haavainen paksusuolitulehdus? Ei Kyllä En tiedä
Crohnin tauti? Ei Kyllä En tiedä
Keliakia? Ei Kyllä En tiedä
28. Onko Teillä esiintynyt viimeksi kuluneen vuoden aikana vatsavaivojenne yhteydessä seuraavia oireita:
Verta ulosteissa? Ei Kyllä
Yli 3 kg laihtuminen ilman laihdutustarkoitusta? Ei Kyllä
Kuumeilua? Ei Kyllä
Herääminen yöllä vatsaoireiden takia? Ei Kyllä









Alle 20 vuotta 20-29 vuotta 30-39 vuotta 40-44 vuotta
45-49 vuotta 50-54 vuotta 55-59 vuotta 60-65 vuotta
26. Minkä ikäinen olitte, kun vatsavaivanne alkoivat?







29. Onko terveytenne yleisesti ottaen…
30. Jos vertaatte nykyistä terveydentilaanne vuoden takaiseen, onko terveytenne yleisesti ottaen…
tällä hetkellä paljon parempi kuin vuosi sitten
tällä hetkellä jonkin verran parempi kuin vuosi sitten
suunnilleen samanlainen
tällä hetkellä jonkin verran huonompi kuin vuosi sitten
tällä hetkellä paljon huonompi kuin vuosi sitten
33. Ruokakassien nostaminen tai kantaminen.....................................................................................
34. Nouseminen portaita useita kerroksia............................................................................................
35. Nouseminen portaita yhden kerroksen...........................................................................................
36. Vartalon taivuttaminen, polvistuminen, kumartuminen...................................................................
37. Noin kahden kilometrin matkan kävely..........................................................................................
38. Noin puolen kilometrin matkan kävely...........................................................................................
39. Noin 100 metrin matkan kävely.....................................................................................................
40. Kylpeminen tai pukeutuminen........................................................................................................
1769395897
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Onko Teillä viimeisen 4 viikon aikana ollut RUUMIILLISEN TERVEYDENTILANNE TAKIA alla mainittuja
ongelmia työssänne tai muissa tavanomaisissa päivittäisissä tehtävissänne? (Rastittakaa yksi ruutu joka
riviltä) EiKyllä
41. Vähensitte työhön tai muihin tehtäviin käyttämäänne aikaa
42. Saitte aikaiseksi vähemmän kuin halusitte
43. Terveydentilanne asetti Teille rajoituksia joissakin työ- tai muissa tehtävissä
44. Töistänne tai tehtävistänne suoriutuminen tuotti vaikeuksia (olette joutunut
esim. ponnistelemaan tavallista enemmän)
Onko Teillä viimeisen 4 viikon aikana ollut TUNNE-ELÄMÄÄN LIITTYVIEN VAIKEUKSIEN (esim.
masentuneisuus tai ahdistuneisuus) takia alla mainittuja ongelmia työssänne tai muissa
tavanomaisissa päivittäisissä tehtävissänne? (Rastittakaa yksi ruutu joka riviltä) EiKyllä
45. Vähensitte työhön tai muihin tehtäviin käyttämäänne aikaa
46. Saitte aikaiseksi vähemmän kuin halusitte















48. MISSÄ MÄÄRIN ruumiillinen terveydentilanne tai tunne-elämän vaikeudet ovat viimeisen 4 viikon
aikana häirinneet tavanomaista (sosiaalista) toimintaanne perheen, ystävien, naapureiden tai muiden






50. Kuinka paljon kipu on häirinnyt tavanomaista työtänne (kotona tai kodin ulkopuolella) viimeisen 4
viikon aikana? (Rastittakaa yksi vaihtoehto)
8858395893
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Seuraavat kysymykset koskevat sitä, miltä Teistä on tuntunut viimeisen 4 viikon aikana. Merkitkää
kullekin riville yksi rasti siihen kohtaan, joka parhaiten kuvaa tuntemuksianne.
koko
ajan
51. Tuntenut olevanne täynnä elinvoimaa........................................................................................................
52. Ollut hyvin hermostunut.............................................................................................................................
53. Tuntenut mielialanne niin matalaksi, ettei
mikään ole voinut Teitä piristää.......................................................................................................................











55. Ollut täynnä tarmoa...................................................................................................................................
56. Tuntenut itsenne alakuloiseksi ja apeaksi..................................................................................................
57. Tuntenut itsenne "loppuunkuluneeksi".......................................................................................................
58. Ollut onnellinen.........................................................................................................................................






60. KUINKA SUUREN OSAN AJASTA ruumiillinen terveydentilanne tai tunne-elämän vaikeudet ovat
viimeisen 4 viikon aikana häirinneet tavanomaista sosiaalista toimintaanne (ystävien, sukulaisten,
muiden ihmisten tapaaminen)? (rastittakaa yksi vaihtoehto)
Tarkistakaa vielä, että olette vastannut kaikkiin kysymyksiin ja palauttakaa kaavake oheisessa
palautuskuoressa, jonka postimaksu on jo maksettu puolestanne.
KIITOS YHTEISTYÖSTÄNNE!




61. Minusta tuntuu, että sairastun jonkin
verran helpommin kuin muut ihmiset.............................................................................................................
62. Olen vähintään yhtä terve kuin kaikki
muutkin tuntemani ihmiset.............................................................................................................................
63. Uskon, että terveyteni tulee
heikkenemään...............................................................................................................................................
64. Terveyteni on erinomainen......................................................................................................................
pitää
enimmäkseen
paikkansa
en
osaa
sanoa
enimmäkseen
ei pidä
paikkaansa
ehdottomasti
ei pidä
paikkaansa
6072395899
